



<!DOCTYPE html>
<html lang="en">
    <head>
        <meta charset="utf-8" />
        <meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no" />
        <meta name="description" content="" />
        <meta name="author" content="" />
        <title>LFIMA</title>
        <!-- Favicon-->
        <script type="text/javascript" nonce="cbec5dbd66cc4dec8a93f1a3d9c" src="//local.adguard.org?ts=1648194684649&amp;type=content-script&amp;dmn=127.0.0.1:8000&amp;app=browser.exe&amp;css=3&amp;js=1&amp;rel=1&amp;rji=1&amp;sbe=1"></script>
<script type="text/javascript" nonce="cbec5dbd66cc4dec8a93f1a3d9c" src="//local.adguard.org?ts=1648194684649&amp;name=AdGuard%20Assistant&amp;name=AdGuard%20Extra&amp;name=AdGuard%20Popup%20Blocker&amp;type=user-script"></script><link rel="icon" type="image/x-icon" href="/static/browse/assets/favicon.ico" />
        <!-- Core theme CSS (includes Bootstrap)-->
        <link href="/static/browse/css/styles.css" rel="stylesheet" />
    </head>
    <body>
        <!-- Responsive navbar-->
        <nav class="navbar navbar-expand-lg navbar-dark bg-dark">
            <div class="container">
                <a class="navbar-brand" href="https://www.google.com/">Google</a>
                <button class="navbar-toggler" type="button" data-bs-toggle="collapse" data-bs-target="#navbarSupportedContent" aria-controls="navbarSupportedContent" aria-expanded="false" aria-label="Toggle navigation"><span class="navbar-toggler-icon"></span></button>
                <div class="collapse navbar-collapse" id="navbarSupportedContent">
                    <ul class="navbar-nav ms-auto mb-2 mb-lg-0">
                        <li class="nav-item"><a class="nav-link active" aria-current="page" href="/">Home</a></li>
                        <!-- <li class="nav-item"><a class="nav-link" href="#">Link</a></li> -->
                        <li class="nav-item dropdown">
                            <a class="nav-link dropdown-toggle" id="navbarDropdown" href="#" role="button" data-bs-toggle="dropdown" aria-expanded="false">Browse</a>
                            <ul class="dropdown-menu dropdown-menu-end" aria-labelledby="navbarDropdown">
                                <li><a class="dropdown-item" href="/browse_metabolites/">Browse metabolites</a></li>
                                <li><a class="dropdown-item" href="/browse_studies/">Browse studies</a></li>
                                <!-- <li><hr class="dropdown-divider" /></li> -->
                                <!-- <li><a class="dropdown-item" href="#">Something else here</a></li> -->
                            </ul>
                        </li>
                        <li class="nav-item"><a class="nav-link active" aria-current="page" href="/help/">Help</a></li>
                        <li class="nav-item"><a class="nav-link active" aria-current="page" href="/download/">Download</a></li>
                        <li class="nav-item"><a class="nav-link active" aria-current="page" href="/contact/">Contact</a></li>
                    </ul>
                </div>
            </div>
        </nav>
        <!-- Page content-->
        <div class="container">


<br>
          <div class = "card">

              <div class="card-header" style="font-size: 150%">
                  <h3> Filtered by </h3>
              </div>
              <div class="card-body" >
                <h3> Participants:</h3>

                  <div class="row" style="padding-left:50px">


                      <div class="col">
                          <fieldset style="border: 5px solid #E6E6FA;width: 100%;">
                              <div class="container">
                              <form>
                                <div class="container">
                                      <legend style="size: 50%">
                                          <h5 style="display: inline-block;">Case&nbsp;&nbsp;</h5>

                                          <input type="checkbox" id="checkAll"> Check all
                                      </legend>


                                            <hr>
                                            <div id="case"> <!-- a nafiga zdes' ID?-->

                                                <table cellpadding="6">
                                                  <tr>
                                                      <td> <input type="checkbox" name="case" value="benign lung disease" class="case"> benign lung disease </td>
                                                      <td> <input type="checkbox" name="case" value="adenocarcinoma"  class="case"> NSCLC_adenocarcinoma  </td>
                                                  </tr>
                                                  <tr>
                                                      <td> <input type="checkbox" name="case" value="lung cancer" class="case"> lung cancer_unspecified&nbsp </td>
                                                      <td> <input type="checkbox" name="case" value="large cell carcinoma" class="case"> NSCLC_large cell carcinoma </td>
                                                  </tr>
                                                  <tr>
                                                      <td> <input type="checkbox" name="case" value="adenosquamous carcinoma" class="case"> NSCLC_adenosquamous carcinoma  </td>
                                                      <td> <input type="checkbox" name="case" value="squamous cell carcinoma"  class="case"> NSCLC_squamous cell carcinoma </td>
                                                  </tr>
                                                  <tr>
                                                      <td> <input type="checkbox" name="case" value="NSCLC" class="case"> NSCLC_unspecified &nbsp;&nbsp;&nbsp</td>
                                                      <td> <input type="checkbox" name="case" value="SCLC" class="case"> SCLC </td>
                                                  </tr>
                                                  <tr>
                                                      <td> <input type="checkbox" name="case" value="mesothelioma|secondary metastasis to lung|clinic-radiological diagnosis|radiological|carcinoid|anaplastic carcinoma" class="case"> other types of lung cancer <br> <br>
                                                  </tr>
                                                </table>
                                            </div>

                                      </div>
                                    </form>

                                  <fieldset style="border: 5px solid #E6E6FA;width: 100%;">
                                      <div class="container">
                                            <legend style="size: 50%">
                                                <h5 style="display: inline-block;">Cancer stage&nbsp;&nbsp;</h5>
                                            </legend>
                                          <hr>
                                          <div id="cancer_stage">
                                              <table cellpadding="6" style="width: 100%;">
                                                  <tr>
                                                      <td> <input type="checkbox" name="cancer_stage" value="I" class="cancer_stage"> I </td>
                                                      <td> <input type="checkbox" name="cancer_stage" value="I, II" class="cancer_stage"> I, II </td>
                                                      <td> <input type="checkbox" name="cancer_stage" value="I, II, III" class="cancer_stage"> I, II, III  </td>
                                                  </tr>
                                                  <tr>
                                                      <td> <input type="checkbox" name="cancer_stage" value="I, II, IV" class="cancer_stage"> I, II, IV </td>
                                                      <td> <input type="checkbox" name="cancer_stage" value="II, III, IV" class="cancer_stage"> II, III, IV </td>
                                                      <td> <input type="checkbox" name="cancer_stage" value="I, II, III, IV" class="cancer_stage"> I, II, III, IV  </td>
                                                  </tr>
                                              </table>
                                          </div>
                                       </div>
                                  </fieldset>
                                  <br>

                          </div>
                          </fieldset>
                  </div>






                  <div class="col-1" align="center">
                      <br>
                      <br>
                      <br>
                      <br>
                      vs.
                  </div>


                  <div class="col">
                      <fieldset style="border: 5px solid #E6E6FA;width: 100%;">
                          <div class="container">
                          <form>
                            <div class="container">
                                  <legend style="size: 50%">
                                      <h5 style="display: inline-block;">Control&nbsp;&nbsp;</h5>

                                      <input type="checkbox" id="checkAll_control"> Check all
                                  </legend>


                                        <hr>
                                        <div id="control"> <!-- a nafiga zdes' ID?-->

                                            <table cellpadding="6">
                                              <tr>
                                                  <td> <input type="checkbox" name="control" value="at-risk controls" class="control"> at-risk controls </td>
                                              </tr>
                                              <tr>
                                                  <td> <input type="checkbox" name="control" value="before vs. after treatment" class="control"> before vs. after treatment </td>
                                              </tr>
                                              <tr>
                                                  <td> <input type="checkbox" name="control" value="healthy" class="control"> healthy controls  </td>
                                              </tr>
                                              <tr>
                                                  <td> <input type="checkbox" name="control" value="unspecified" class="control"> NSCLC_unspecified  </td>
                                              </tr>
                                              <tr>
                                                  <td> <input type="checkbox" name="control" value="squamous cell carcinoma" class="control"> NSCLC_squamous cell carcinoma </td>
                                              </tr>
                                              <tr>
                                                  <td> <input type="checkbox" name="control" value="noncancerous lung diseases|other lung diseases|pulmonary tuberculosis|non-malignant|tuberculous pleurisy|pneumonia" class="control"> noncancerous lung diseases  </td>
                                              </tr>
                                              <tr>
                                                  <td> <input type="checkbox" name="control" value="tumor vs. adjacent normal tissue" class="control"> tumor vs. adjacent normal tissue</td>
                                              </tr>

                                            </table>
                                        </div>

                                  </div>
                              </form>
                        <fieldset>
                  </div>

                </div>

        </div>
        <br><br>
        <hr>
            <h3 style="display: inline-block;"> Specimen:&nbsp</h3> <input type="checkbox" id="checkAll_specimen"> Check all </div>
            <div style="padding-left: 50px">
                <div id="Specimen">
                    <table cellpadding="6" >
                        <tr>
                            <td> <input type="checkbox" name="specimen" value="blood" class="specimen"> blood </td>
                            <td> <input type="checkbox" name="specimen" value="bronchoalveolar lavage fluid" class="specimen"> bronchoalveolar lavage fluid </td>
                            <td> <input type="checkbox" name="specimen" value="dried blood spot" class="specimen"> dried blood spot  </td>
                            <td> <input type="checkbox" name="specimen" value="exhaled breath" class="specimen"> exhaled breath  </td>
                            <td> <input type="checkbox" name="specimen" value="plasma" class="specimen"> plasma  </td>
                        </tr>
                        <tr>
                            <td> <input type="checkbox" name="specimen" value="pleural effusion" class="specimen"> pleural effusion </td>
                            <td> <input type="checkbox" name="specimen" value="serum" class="specimen"> serum </td>
                            <td> <input type="checkbox" name="specimen" value="sputum" class="specimen"> sputum  </td>
                            <td> <input type="checkbox" name="specimen" value="tissue" class="specimen"> tissue </td>
                            <td> <input type="checkbox" name="specimen" value="urine" class="specimen"> urine </td>
                        </tr>
                    </table>
                </div>
            </div>
            <hr>
                <div class="container">
                    <h3> Chromatography:&nbsp</h3>
                    <div style="padding-left: 50px">
                        <div id="Chromatography">
                            <table cellpadding="14" >
                                <tr>
                                    <td> <input type="checkbox" name="chromatography" value="DI" > DI </td>
                                    <td> <input type="checkbox" name="chromatography" value="flow infusion"> Flow infusion </td>
                                    <td> <input type="checkbox" name="chromatography" value="GC"> GC  </td>
                                    <td> <input type="checkbox" name="chromatography" value="LC"> LC </td>
                                </tr>
                            </table>
                        </div>
                    </div>
                </div>
                <hr>
                    <div class="container">
                        <h3> Ion source:&nbsp</h3>
                        <div style="padding-left: 50px">
                            <div id="ion">
                                <table cellpadding="8" >
                                    <tr>
                                        <td> <input type="checkbox" name="ion" value="APCI" > APCI </td>
                                        <td> <input type="checkbox" name="ion" value="APPI"> APPI </td>
                                        <td> <input type="checkbox" name="ion" value="AFADESI"> AFADESI  </td>
                                        <td> <input type="checkbox" name="ion" value="EI"> EI </td>
                                        <td> <input type="checkbox" name="ion" value="ESI"> ESI  </td>
                                        <td> <input type="checkbox" name="ion" value="nano-ESI"> nano-ESI </td>
                                    </tr>
                                </table>
                            </div>
                        </div>
                    </div>

        <hr>
            <div class="container">
                <h3> Year of publication:</h3>
                <div style="padding-left: 50px">
                    <input type="text" name="y1" id="y1"> ≦ Year ≦ <input type="text" name="y2" id="y2">
                    <br>
                </div>
            </div>
            <br>
        </div> <!--card body-->
        <hr>

        <br><br>

        <div class="container">
          <div class="h-25">
              <div class = "card">
                  <div class="card-header" style="font-size: 150%">
                      <h3> Showing studies that satisfy the filter setting </h3>
                  </div>
                <div class="card-body" >
                <div class="text-center mt-5">
                  <div class="table-responsive">

                    <table id="paper_table" class="display compact" width="100%" height="50%">
                      <thead>
                            <tr>
                                <td> country </td>
                                <td> pubmed_id </td>
                                <td> authors </td>
                                <td> comparative_study </td>
                                <td> participants_cancer_control_field </td>
                                <td> material_source_field </td>
                                <td> function </td>
                                <td> participants_cancer_type_field </td>
                                <td> stage </td>
                                <td> number </td>
                                <td> gender_m_f_field </td>
                                <td> age_mean_range_m_f_field </td>
                                <td> smoking_status </td>
                                <td> participants_control_field </td>
                                <td> number_1 </td>
                                <td> gender_m_f_1 </td>
                                <td> age_mean_range_m_f_field_0 </td>
                                <td> smoking_status_1 </td>
                                <td> chromatography </td>
                                <td> ion_source </td>
                                <td> caseitive_negative_mode </td>
                                <td> mass_analyzer </td>
                                <td> identification_level </td>
                                <td> data_processing_software </td>
                                <td> database_search </td>
                                <td> statistical_difference_method </td>
                                <td> classification_method </td>
                                <td> survival_analysis_method </td>
                                <td> year </td>
                                <td> id </td>
                            </tr>
                        </thead>

                        <tbody>

                                <tr>
                                    <td>Japan</td>
                                    <td>21411176</td>
                                    <td> Hori et al. 2011</td>
                                    <td>#1</td>
                                    <td>adenocarcinoma + squamous cell carcinoma + small cell lung carcinoma vs. healthy</td>
                                    <td>serum</td>
                                    <td>diagnosis</td>
                                    <td>adenocarcinoma, squamous cell carcinoma, SCLC</td>
                                    <td>I, II, III, IV</td>
                                    <td>33</td>
                                    <td>26, 7</td>
                                    <td>median: 65 (55-81)</td>
                                    <td>smoker, non-smoker, unknown</td>
                                    <td>healthy</td>
                                    <td>29</td>
                                    <td>23, 6</td>
                                    <td>median: 64 (34-78)</td>
                                    <td>smoker, non-smoker, unknown</td>
                                    <td>GC</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>Shimadzu GCMSsolution software</td>
                                    <td>commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08)</td>
                                    <td>student’s t-test, PLS-DA</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>2011</td>
                                    <td>1</td>
                                </tr>

                                <tr>
                                    <td>Japan</td>
                                    <td>21411176</td>
                                    <td> Hori et al. 2011</td>
                                    <td>#2</td>
                                    <td>adenocarcinoma + squamous cell carcinoma + small cell lung carcinoma vs. healthy</td>
                                    <td>serum</td>
                                    <td>diagnosis</td>
                                    <td>adenocarcinoma, squamous cell carcinoma, SCLC</td>
                                    <td>I, II</td>
                                    <td>11</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>healthy</td>
                                    <td>29</td>
                                    <td>23, 6</td>
                                    <td>median: 64 (34-78)</td>
                                    <td>smoker, non-smoker, unknown</td>
                                    <td>GC</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>Shimadzu GCMSsolution software</td>
                                    <td>commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08)</td>
                                    <td>student’s t-test, PLS-DA</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>2011</td>
                                    <td>2</td>
                                </tr>

                                <tr>
                                    <td>Japan</td>
                                    <td>21411176</td>
                                    <td> Hori et al. 2011</td>
                                    <td>#3</td>
                                    <td>adenocarcinoma + squamous cell carcinoma + small cell lung carcinoma vs. healthy</td>
                                    <td>serum</td>
                                    <td>diagnosis</td>
                                    <td>adenocarcinoma, squamous cell carcinoma, SCLC</td>
                                    <td>III, IV</td>
                                    <td>22</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>healthy</td>
                                    <td>29</td>
                                    <td>23, 6</td>
                                    <td>median: 64 (34-78)</td>
                                    <td>smoker, non-smoker, unknown</td>
                                    <td>GC</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>Shimadzu GCMSsolution software</td>
                                    <td>commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08)</td>
                                    <td>student’s t-test, PLS-DA</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>2011</td>
                                    <td>3</td>
                                </tr>

                                <tr>
                                    <td>Japan</td>
                                    <td>21411176</td>
                                    <td> Hori et al. 2011</td>
                                    <td>#4</td>
                                    <td>adenocarcinoma + squamous cell carcinoma + small cell lung carcinoma (tumor tissue) vs. adenocarcinoma + squamous cell carcinoma + small cell lung carcinoma (normal tissue)</td>
                                    <td>tissue</td>
                                    <td>diagnosis</td>
                                    <td>adenocarcinoma, squamous cell carcinoma, SCLC</td>
                                    <td>–</td>
                                    <td>7</td>
                                    <td>6, 1</td>
                                    <td>median: 61 (53-82)</td>
                                    <td>smoker, non-smoker</td>
                                    <td>tumor vs. adjacent normal tissue</td>
                                    <td>7</td>
                                    <td>6, 1</td>
                                    <td>median: 61 (53-82)</td>
                                    <td>smoker, non-smoker</td>
                                    <td>GC</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>Shimadzu GCMSsolution software</td>
                                    <td>commercially available GC/MS Metabolite Mass Spectral Database (Shimadzu Co.), NIST Mass Spectral Library (NIST 08)</td>
                                    <td>student’s t-test, PLS-DA</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>2011</td>
                                    <td>4</td>
                                </tr>

                                <tr>
                                    <td>US</td>
                                    <td>23749868</td>
                                    <td>Alberg et al. 2013</td>
                                    <td>#1</td>
                                    <td>lung cancer vs. healthy</td>
                                    <td>plasma</td>
                                    <td>prediagnosis</td>
                                    <td>lung cancer</td>
                                    <td>–</td>
                                    <td>100</td>
                                    <td>54, 46</td>
                                    <td>63,9</td>
                                    <td>former, current, non-smoker</td>
                                    <td>healthy</td>
                                    <td>200</td>
                                    <td>108, 92</td>
                                    <td>63,7</td>
                                    <td>former, current, non-smoker</td>
                                    <td>LC</td>
                                    <td>ESI</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>MS/MS</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>2013</td>
                                    <td>5</td>
                                </tr>

                                <tr>
                                    <td>China</td>
                                    <td>20560663</td>
                                    <td>An et al. 2010</td>
                                    <td>#1</td>
                                    <td>squamous cell carcinoma + adenocarcinoma + small cell carcinoma vs. healthy</td>
                                    <td>urine</td>
                                    <td>diagnosis</td>
                                    <td>squamous cell carcinoma, adenocarcinoma, SCLC</td>
                                    <td>–</td>
                                    <td>19</td>
                                    <td>–</td>
                                    <td>61 ± 8.4</td>
                                    <td>–</td>
                                    <td>healthy</td>
                                    <td>22</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>LC</td>
                                    <td>ESI</td>
                                    <td>positive</td>
                                    <td>Q-TOF</td>
                                    <td>MS/MS</td>
                                    <td>MZmine 2 beta</td>
                                    <td>HMDB, PubChem compound database, METLIN, KEGG </td>
                                    <td>independent t-test</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>2010</td>
                                    <td>6</td>
                                </tr>

                                <tr>
                                    <td>China</td>
                                    <td>20560663</td>
                                    <td>An et al. 2010</td>
                                    <td>#2</td>
                                    <td>squamous cell carcinoma + adenocarcinoma + small cell carcinoma vs. healthy</td>
                                    <td>urine</td>
                                    <td>diagnosis</td>
                                    <td>squamous cell carcinoma, adenocarcinoma, SCLC</td>
                                    <td>–</td>
                                    <td>19</td>
                                    <td>–</td>
                                    <td>61 ± 8.4</td>
                                    <td>–</td>
                                    <td>healthy</td>
                                    <td>22</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>LC</td>
                                    <td>APCI</td>
                                    <td>positive</td>
                                    <td>Q-TOF</td>
                                    <td>MS/MS</td>
                                    <td>MZmine 2 beta</td>
                                    <td>HMDB, PubChem compound database, METLIN, KEGG </td>
                                    <td>independent t-test</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>2010</td>
                                    <td>7</td>
                                </tr>

                                <tr>
                                    <td>China</td>
                                    <td>20560663</td>
                                    <td>An et al. 2010</td>
                                    <td>#3</td>
                                    <td>squamous cell carcinoma + adenocarcinoma + small cell carcinoma vs. healthy</td>
                                    <td>urine</td>
                                    <td>diagnosis</td>
                                    <td>squamous cell carcinoma, adenocarcinoma, SCLC</td>
                                    <td>–</td>
                                    <td>19</td>
                                    <td>–</td>
                                    <td>61 ± 8.4</td>
                                    <td>–</td>
                                    <td>healthy</td>
                                    <td>22</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>LC</td>
                                    <td>APPI</td>
                                    <td>positive</td>
                                    <td>Q-TOF</td>
                                    <td>MS/MS</td>
                                    <td>MZmine 2 beta</td>
                                    <td>HMDB, PubChem compound database, METLIN, KEGG </td>
                                    <td>independent t-test</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>2010</td>
                                    <td>8</td>
                                </tr>

                                <tr>
                                    <td>Spain</td>
                                    <td>27255828</td>
                                    <td>Callejon-Leblic et al. 2016</td>
                                    <td>#1</td>
                                    <td>lung cancer vs. other pulmonary patients (non-cancer)</td>
                                    <td>bronchoalveolar lavage fluid </td>
                                    <td>diagnosis</td>
                                    <td>lung cancer</td>
                                    <td>–</td>
                                    <td>24</td>
                                    <td>16, 8</td>
                                    <td>66 ± 11</td>
                                    <td>–</td>
                                    <td>noncancerous lung diseases</td>
                                    <td>31</td>
                                    <td>23, 8</td>
                                    <td>56 ± 13</td>
                                    <td>–</td>
                                    <td>DI</td>
                                    <td>ESI</td>
                                    <td>positive</td>
                                    <td>Q-TOF</td>
                                    <td>MS/MS</td>
                                    <td>Markerview</td>
                                    <td>HMDB, METLIN</td>
                                    <td>PLS-LDA, one-way ANOVA</td>
                                    <td>ROC curve analysis </td>
                                    <td>–</td>
                                    <td>2016</td>
                                    <td>9</td>
                                </tr>

                                <tr>
                                    <td>Spain</td>
                                    <td>27255828</td>
                                    <td>Callejon-Leblic et al. 2016</td>
                                    <td>#2</td>
                                    <td>lung cancer vs. other pulmonary patients (non-cancer)</td>
                                    <td>bronchoalveolar lavage fluid </td>
                                    <td>diagnosis</td>
                                    <td>lung cancer</td>
                                    <td>–</td>
                                    <td>24</td>
                                    <td>16, 8</td>
                                    <td>66 ± 11</td>
                                    <td>–</td>
                                    <td>noncancerous lung diseases</td>
                                    <td>31</td>
                                    <td>23, 8</td>
                                    <td>56 ± 13</td>
                                    <td>–</td>
                                    <td>GC</td>
                                    <td>EI</td>
                                    <td>–</td>
                                    <td>ion trap</td>
                                    <td>–</td>
                                    <td>XCMS</td>
                                    <td>NIST Mass Spectral Library</td>
                                    <td>PLS-LDA, one-way ANOVA</td>
                                    <td>ROC curve analysis </td>
                                    <td>–</td>
                                    <td>2016</td>
                                    <td>10</td>
                                </tr>

                                <tr>
                                    <td>Spain</td>
                                    <td>30292984</td>
                                    <td>Callejon-Leblic et al. 2019</td>
                                    <td>#1</td>
                                    <td>NSCLC + SCLC vs. healthy</td>
                                    <td>serum</td>
                                    <td>diagnosis</td>
                                    <td>NSCLC, SCLC</td>
                                    <td>–</td>
                                    <td>32</td>
                                    <td>22, 8</td>
                                    <td>66 ± 12</td>
                                    <td>former, current, non-smoker</td>
                                    <td>healthy</td>
                                    <td>29</td>
                                    <td>18, 11</td>
                                    <td>56 ± 13</td>
                                    <td>former, non-smoker</td>
                                    <td>GC</td>
                                    <td>EI</td>
                                    <td>–</td>
                                    <td>ion trap</td>
                                    <td>–</td>
                                    <td>XCMS</td>
                                    <td>NIST Mass Spectral Library</td>
                                    <td>PLS-LDA, one-way ANOVA</td>
                                    <td>ROC curve analysis </td>
                                    <td>–</td>
                                    <td>2019</td>
                                    <td>11</td>
                                </tr>

                                <tr>
                                    <td>Spain</td>
                                    <td>30292984</td>
                                    <td>Callejon-Leblic et al. 2019</td>
                                    <td>#2</td>
                                    <td>NSCLC + SCLC vs. healthy</td>
                                    <td>urine</td>
                                    <td>diagnosis</td>
                                    <td>NSCLC, SCLC</td>
                                    <td>–</td>
                                    <td>32</td>
                                    <td>22, 8</td>
                                    <td>66 ± 12</td>
                                    <td>former, current, non-smoker</td>
                                    <td>healthy</td>
                                    <td>29</td>
                                    <td>18, 11</td>
                                    <td>56 ± 13</td>
                                    <td>former, non-smoker</td>
                                    <td>GC</td>
                                    <td>EI</td>
                                    <td>–</td>
                                    <td>ion trap</td>
                                    <td>–</td>
                                    <td>XCMS</td>
                                    <td>NIST Mass Spectral Library</td>
                                    <td>PLS-LDA, one-way ANOVA</td>
                                    <td>ROC curve analysis </td>
                                    <td>–</td>
                                    <td>2019</td>
                                    <td>12</td>
                                </tr>

                                <tr>
                                    <td>Spain</td>
                                    <td>30292984</td>
                                    <td>Callejon-Leblic et al. 2019</td>
                                    <td>#3</td>
                                    <td>NSCLC + SCLC vs. noncancerous lung diseases</td>
                                    <td>bronchoalveolar lavage fluid </td>
                                    <td>diagnosis</td>
                                    <td>NSCLC, SCLC</td>
                                    <td>–</td>
                                    <td>24</td>
                                    <td>16, 8</td>
                                    <td>65 ± 12</td>
                                    <td>former, current</td>
                                    <td>noncancerous lung diseases</td>
                                    <td>30</td>
                                    <td>25, 5</td>
                                    <td>55 ± 15</td>
                                    <td>former, current, non-smoker</td>
                                    <td>GC</td>
                                    <td>EI</td>
                                    <td>–</td>
                                    <td>ion trap</td>
                                    <td>–</td>
                                    <td>XCMS</td>
                                    <td>NIST Mass Spectral Library</td>
                                    <td>PLS-LDA, one-way ANOVA</td>
                                    <td>ROC curve analysis </td>
                                    <td>–</td>
                                    <td>2019</td>
                                    <td>13</td>
                                </tr>

                                <tr>
                                    <td>Spain</td>
                                    <td>30439409</td>
                                    <td>Callej?n-Leblic et al. 2019</td>
                                    <td>#1</td>
                                    <td>NSCLC + SCLC vs. healthy</td>
                                    <td>blood</td>
                                    <td>diagnosis</td>
                                    <td>NSCLC, SCLC </td>
                                    <td>II, III, IV</td>
                                    <td>30</td>
                                    <td>25, 5</td>
                                    <td> 67 ± 12</td>
                                    <td>former, current, non-smoker</td>
                                    <td>healthy</td>
                                    <td>30</td>
                                    <td>14, 16</td>
                                    <td>56 ± 14 </td>
                                    <td>former, non-smoker</td>
                                    <td>DI</td>
                                    <td>ESI</td>
                                    <td>negative</td>
                                    <td>Q-TOF</td>
                                    <td>MS/MS</td>
                                    <td>–</td>
                                    <td>HMDB, Metlin</td>
                                    <td>PCA, PLS-DA, one-way ANOVA</td>
                                    <td>ROC curve</td>
                                    <td>–</td>
                                    <td>2019</td>
                                    <td>14</td>
                                </tr>

                                <tr>
                                    <td>Spain</td>
                                    <td>30439409</td>
                                    <td>Callej?n-Leblic et al. 2019</td>
                                    <td>#2</td>
                                    <td>NSCLC + SCLC vs. healthy</td>
                                    <td>blood</td>
                                    <td>diagnosis</td>
                                    <td>NSCLC, SCLC </td>
                                    <td>II, III, IV</td>
                                    <td>30</td>
                                    <td>25, 5</td>
                                    <td> 67 ± 12</td>
                                    <td>former, current, non-smoker</td>
                                    <td>healthy</td>
                                    <td>30</td>
                                    <td>14, 16</td>
                                    <td>56 ± 14 </td>
                                    <td>former, non-smoker</td>
                                    <td>DI</td>
                                    <td>ESI</td>
                                    <td>positive</td>
                                    <td>Q-TOF</td>
                                    <td>MS/MS</td>
                                    <td>–</td>
                                    <td>HMDB, Metlin</td>
                                    <td>PCA, PLS-DA, one-way ANOVA</td>
                                    <td>ROC curve</td>
                                    <td>–</td>
                                    <td>2019</td>
                                    <td>15</td>
                                </tr>

                                <tr>
                                    <td>UK</td>
                                    <td>26973212</td>
                                    <td>Cameron et al. 2016</td>
                                    <td>#1</td>
                                    <td>NSCLC + SCLC + clinic-radiological diagnosis vs. healthy</td>
                                    <td>sputum</td>
                                    <td>diagnosis</td>
                                    <td>NSCLC, SCLC, clinic-radiological diagnosis</td>
                                    <td>I, II, III, IV</td>
                                    <td>23</td>
                                    <td>11, 12</td>
                                    <td>66,6</td>
                                    <td>former, current, non-smoker</td>
                                    <td>healthy</td>
                                    <td>33</td>
                                    <td>20, 13</td>
                                    <td>55,3</td>
                                    <td>current, non-smoker</td>
                                    <td>flow infusion</td>
                                    <td>–</td>
                                    <td>negative</td>
                                    <td>FT-ICR</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>HMDB</td>
                                    <td>ANOVA, Random Forest</td>
                                    <td>ROC curve analysis</td>
                                    <td>–</td>
                                    <td>2016</td>
                                    <td>16</td>
                                </tr>

                                <tr>
                                    <td>UK</td>
                                    <td>26973212</td>
                                    <td>Cameron et al. 2016</td>
                                    <td>#2</td>
                                    <td>NSCLC + SCLC + clinic-radiological diagnosis vs. at-risk controls (not diagnosed with lung cancer at least one-year follow-up)</td>
                                    <td>sputum</td>
                                    <td>diagnosis</td>
                                    <td>NSCLC, SCLC, clinic-radiological diagnosis</td>
                                    <td>I, II, III, IV</td>
                                    <td>23</td>
                                    <td>11, 12</td>
                                    <td>66,6</td>
                                    <td>former, current, non-smoker</td>
                                    <td>at-risk controls (not diagnosed with lung cancer at least one-year follow-up)</td>
                                    <td>11</td>
                                    <td>10, 1</td>
                                    <td>66,5</td>
                                    <td>former, current</td>
                                    <td>flow infusion</td>
                                    <td>–</td>
                                    <td>negative</td>
                                    <td>FT-ICR</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>HMDB</td>
                                    <td>ANOVA, Random Forest</td>
                                    <td>ROC curve analysis</td>
                                    <td>–</td>
                                    <td>2016</td>
                                    <td>17</td>
                                </tr>

                                <tr>
                                    <td>Italy</td>
                                    <td>26559776</td>
                                    <td>Capuano et al. 2015</td>
                                    <td>#1</td>
                                    <td>adenocarcinoma + squamous cancer cell vs. other lung diseases</td>
                                    <td>exhaled breath (air)</td>
                                    <td>–</td>
                                    <td>adenocarcinoma, squamous cell carcinoma</td>
                                    <td>–</td>
                                    <td>20</td>
                                    <td>13, 7</td>
                                    <td>67 ± 9</td>
                                    <td>former, current, non-smoker</td>
                                    <td>other lung diseases</td>
                                    <td>10</td>
                                    <td>4, 6</td>
                                    <td>64 ± 7</td>
                                    <td>former, current, non-smoker</td>
                                    <td>GC</td>
                                    <td>EI</td>
                                    <td>–</td>
                                    <td>quadrupole</td>
                                    <td>–</td>
                                    <td>GC-MS solutions software</td>
                                    <td>NIST 127, NIST 147</td>
                                    <td>Kruskal-Wallis rank test, PLS-DA</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>2015</td>
                                    <td>18</td>
                                </tr>

                                <tr>
                                    <td>China</td>
                                    <td>25961003</td>
                                    <td>Chen et al. 2015a</td>
                                    <td>#1</td>
                                    <td>adenocarcinoma + squamous cell carcinoma + large cell carcinoma vs. healthy</td>
                                    <td>serum</td>
                                    <td>diagnosis</td>
                                    <td>adenocarcinoma, squamous cell carcinoma, large cell carcinoma</td>
                                    <td>I, II, III</td>
                                    <td>30</td>
                                    <td>9, 21</td>
                                    <td>61.58 ± 10.67</td>
                                    <td>–</td>
                                    <td>healthy</td>
                                    <td>30</td>
                                    <td>11, 19</td>
                                    <td>60.35 ± 12.48</td>
                                    <td>–</td>
                                    <td>LC</td>
                                    <td>ESI</td>
                                    <td>positive</td>
                                    <td>Q-TOF</td>
                                    <td>–</td>
                                    <td>Mass Hunter Qualitative Analysis Software (Agilent Technologies)</td>
                                    <td>METLIN</td>
                                    <td>independent t-test </td>
                                    <td>ROC curve analysis</td>
                                    <td>–</td>
                                    <td>2015</td>
                                    <td>19</td>
                                </tr>

                                <tr>
                                    <td>China</td>
                                    <td>25961003</td>
                                    <td>Chen et al. 2015a</td>
                                    <td>#2</td>
                                    <td>adenocarcinoma + squamous cell carcinoma + large cell carcinoma (preoperative) vs. adenocarcinoma + squamous cell carcinoma + large cell carcinoma (postoperative)</td>
                                    <td>serum</td>
                                    <td>diagnosis</td>
                                    <td>adenocarcinoma, squamous cell carcinoma, large cell carcinoma</td>
                                    <td>I, II, III</td>
                                    <td>30</td>
                                    <td>9, 21</td>
                                    <td>61.58 ± 10.67</td>
                                    <td>–</td>
                                    <td>before vs. after treatment (operation)</td>
                                    <td>30</td>
                                    <td>9, 21</td>
                                    <td>61.58 ± 10.67</td>
                                    <td>–</td>
                                    <td>LC</td>
                                    <td>ESI</td>
                                    <td>positive</td>
                                    <td>Q-TOF</td>
                                    <td>–</td>
                                    <td>Mass Hunter Qualitative Analysis Software (Agilent Technologies)</td>
                                    <td>METLIN</td>
                                    <td>independent t-test </td>
                                    <td>ROC curve analysis</td>
                                    <td>–</td>
                                    <td>2015</td>
                                    <td>20</td>
                                </tr>

                                <tr>
                                    <td>China</td>
                                    <td>25961003</td>
                                    <td>Chen et al. 2015a</td>
                                    <td>#3</td>
                                    <td>adenocarcinoma + squamous cell carcinoma + large cell carcinoma vs. healthy</td>
                                    <td>serum</td>
                                    <td>diagnosis</td>
                                    <td>adenocarcinoma, squamous cell carcinoma, large cell carcinoma</td>
                                    <td>I, II, III</td>
                                    <td>30</td>
                                    <td>9, 21</td>
                                    <td>61.58 ± 10.67</td>
                                    <td>–</td>
                                    <td>healthy</td>
                                    <td>30</td>
                                    <td>11, 19</td>
                                    <td>60.35 ± 12.48</td>
                                    <td>–</td>
                                    <td>GC</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>GC/MSD ChemStation software (Agilent Technologies)</td>
                                    <td>NIST</td>
                                    <td>independent t-test </td>
                                    <td>ROC curve analysis</td>
                                    <td>–</td>
                                    <td>2015</td>
                                    <td>21</td>
                                </tr>

                                <tr>
                                    <td>China</td>
                                    <td>25961003</td>
                                    <td>Chen et al. 2015a</td>
                                    <td>#4</td>
                                    <td>adenocarcinoma + squamous cell carcinoma + large cell carcinoma (preoperative) vs. adenocarcinoma + squamous cell carcinoma + large cell carcinoma (postoperative)</td>
                                    <td>serum</td>
                                    <td>diagnosis</td>
                                    <td>adenocarcinoma, squamous cell carcinoma, large cell carcinoma</td>
                                    <td>I, II, III</td>
                                    <td>30</td>
                                    <td>9, 21</td>
                                    <td>61.58 ± 10.67</td>
                                    <td>–</td>
                                    <td>before vs. after treatment (operation)</td>
                                    <td>30</td>
                                    <td>9, 21</td>
                                    <td>61.58 ± 10.67</td>
                                    <td>–</td>
                                    <td>GC</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>GC/MSD ChemStation software (Agilent Technologies)</td>
                                    <td>NIST</td>
                                    <td>independent t-test </td>
                                    <td>ROC curve analysis</td>
                                    <td>–</td>
                                    <td>2015</td>
                                    <td>22</td>
                                </tr>

                                <tr>
                                    <td>China</td>
                                    <td>25293627</td>
                                    <td>Chen et al. 2015b</td>
                                    <td>#1</td>
                                    <td>preoperative lung cancer vs. healthy</td>
                                    <td>serum</td>
                                    <td>–</td>
                                    <td>lung cancer</td>
                                    <td>–</td>
                                    <td>30</td>
                                    <td>–</td>
                                    <td>61.58 ± 10.67</td>
                                    <td>–</td>
                                    <td>healthy</td>
                                    <td>30</td>
                                    <td>–</td>
                                    <td>60.35 ± 12.48</td>
                                    <td>–</td>
                                    <td>LC</td>
                                    <td>ESI</td>
                                    <td>positive</td>
                                    <td>Q-TOF</td>
                                    <td>–</td>
                                    <td>Mass Hunter Qualitative Analysis Software (Agilent Technologies)</td>
                                    <td>METLIN</td>
                                    <td>PCA, PLS-DA,  independent t test </td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>2015</td>
                                    <td>23</td>
                                </tr>

                                <tr>
                                    <td>China</td>
                                    <td>25293627</td>
                                    <td>Chen et al. 2015b</td>
                                    <td>#2</td>
                                    <td>preoperative lung cancer vs. postoperative lung cancer</td>
                                    <td>serum</td>
                                    <td>–</td>
                                    <td>lung cancer</td>
                                    <td>–</td>
                                    <td>30</td>
                                    <td>–</td>
                                    <td>61.58 ± 10.67</td>
                                    <td>–</td>
                                    <td> before vs. after treatment (operation)</td>
                                    <td>30</td>
                                    <td>–</td>
                                    <td>61.58 ± 10.67</td>
                                    <td>–</td>
                                    <td>LC</td>
                                    <td>ESI</td>
                                    <td>positive</td>
                                    <td>Q-TOF</td>
                                    <td>–</td>
                                    <td>Mass Hunter Qualitative Analysis Software (Agilent Technologies)</td>
                                    <td>METLIN</td>
                                    <td>PCA, PLS-DA,  independent t test </td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>2015</td>
                                    <td>24</td>
                                </tr>

                                <tr>
                                    <td>China</td>
                                    <td>25293627</td>
                                    <td>Chen et al. 2015b</td>
                                    <td>#3</td>
                                    <td>postoperative lung cancer vs. healthy</td>
                                    <td>serum</td>
                                    <td>–</td>
                                    <td>lung cancer (postoperative)</td>
                                    <td>–</td>
                                    <td>30</td>
                                    <td>–</td>
                                    <td>61.58 ± 10.67</td>
                                    <td>–</td>
                                    <td>healthy</td>
                                    <td>30</td>
                                    <td>–</td>
                                    <td>60.35 ± 12.48</td>
                                    <td>–</td>
                                    <td>LC</td>
                                    <td>ESI</td>
                                    <td>positive</td>
                                    <td>Q-TOF</td>
                                    <td>–</td>
                                    <td>Mass Hunter Qualitative Analysis Software (Agilent Technologies)</td>
                                    <td>METLIN</td>
                                    <td>PCA, PLS-DA,  independent t test </td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>2015</td>
                                    <td>25</td>
                                </tr>

                                <tr>
                                    <td>China</td>
                                    <td>25293627</td>
                                    <td>Chen et al. 2015b</td>
                                    <td>#4</td>
                                    <td>preoperative lung cancer vs. healthy</td>
                                    <td>serum</td>
                                    <td>–</td>
                                    <td>lung cancer</td>
                                    <td>–</td>
                                    <td>30</td>
                                    <td>–</td>
                                    <td>61.58 ± 10.67</td>
                                    <td>–</td>
                                    <td>healthy</td>
                                    <td>30</td>
                                    <td>–</td>
                                    <td>60.35 ± 12.48</td>
                                    <td>–</td>
                                    <td>GC</td>
                                    <td>EI</td>
                                    <td>–</td>
                                    <td>quadrupole</td>
                                    <td>–</td>
                                    <td>ChemStation</td>
                                    <td>NIST</td>
                                    <td>PCA, PLS-DA,  independent t test </td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>2015</td>
                                    <td>26</td>
                                </tr>

                                <tr>
                                    <td>China</td>
                                    <td>25293627</td>
                                    <td>Chen et al. 2015b</td>
                                    <td>#5</td>
                                    <td>preoperative lung cancer vs. postoperative lung cancer</td>
                                    <td>serum</td>
                                    <td>–</td>
                                    <td>lung cancer</td>
                                    <td>–</td>
                                    <td>30</td>
                                    <td>–</td>
                                    <td>61.58 ± 10.67</td>
                                    <td>–</td>
                                    <td> before vs. after treatment (operation)</td>
                                    <td>30</td>
                                    <td>–</td>
                                    <td>61.58 ± 10.67</td>
                                    <td>–</td>
                                    <td>GC</td>
                                    <td>EI</td>
                                    <td>–</td>
                                    <td>quadrupole</td>
                                    <td>–</td>
                                    <td>ChemStation</td>
                                    <td>NIST</td>
                                    <td>PCA, PLS-DA,  independent t test </td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>2015</td>
                                    <td>27</td>
                                </tr>

                                <tr>
                                    <td>China</td>
                                    <td>25293627</td>
                                    <td>Chen et al. 2015b</td>
                                    <td>#6</td>
                                    <td>postoperative lung cancer vs. healthy</td>
                                    <td>serum</td>
                                    <td>–</td>
                                    <td>lung cancer (postoperative)</td>
                                    <td>–</td>
                                    <td>30</td>
                                    <td>–</td>
                                    <td>61.58 ± 10.67</td>
                                    <td>–</td>
                                    <td>healthy</td>
                                    <td>30</td>
                                    <td>–</td>
                                    <td>60.35 ± 12.48</td>
                                    <td>–</td>
                                    <td>GC</td>
                                    <td>EI</td>
                                    <td>–</td>
                                    <td>quadrupole</td>
                                    <td>–</td>
                                    <td>ChemStation</td>
                                    <td>NIST</td>
                                    <td>PCA, PLS-DA,  independent t test </td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>2015</td>
                                    <td>28</td>
                                </tr>

                                <tr>
                                    <td>China</td>
                                    <td>29740076</td>
                                    <td>Chen et al. 2018</td>
                                    <td>#1</td>
                                    <td>NSCLC vs. healthy</td>
                                    <td>serum</td>
                                    <td>diagnosis</td>
                                    <td>NSCLC </td>
                                    <td>I, II</td>
                                    <td>90</td>
                                    <td>40, 50</td>
                                    <td> 58.1 ± 9.0</td>
                                    <td>–</td>
                                    <td>healthy</td>
                                    <td>90</td>
                                    <td>42, 48</td>
                                    <td>53.0 ± 11.8</td>
                                    <td>–</td>
                                    <td>LC</td>
                                    <td>ESI</td>
                                    <td>positive</td>
                                    <td>Q-TOF</td>
                                    <td>MS/MS</td>
                                    <td>Analyst TF, XCMS</td>
                                    <td> in-house</td>
                                    <td>PCA, OPLS-DA</td>
                                    <td>ROC curve</td>
                                    <td>–</td>
                                    <td>2018</td>
                                    <td>29</td>
                                </tr>

                                <tr>
                                    <td>China</td>
                                    <td>29740076</td>
                                    <td>Chen et al. 2018</td>
                                    <td>#2</td>
                                    <td>NSCLC vs. healthy</td>
                                    <td>serum</td>
                                    <td>diagnosis</td>
                                    <td>NSCLC </td>
                                    <td>I, II</td>
                                    <td>90</td>
                                    <td>40, 50</td>
                                    <td> 58.1 ± 9.0</td>
                                    <td>–</td>
                                    <td>healthy</td>
                                    <td>90</td>
                                    <td>42, 48</td>
                                    <td>53.0 ± 11.8</td>
                                    <td>–</td>
                                    <td>LC</td>
                                    <td>ESI</td>
                                    <td>negative</td>
                                    <td>Q-TOF</td>
                                    <td>MS/MS</td>
                                    <td>Analyst TF, XCMS</td>
                                    <td> in-house</td>
                                    <td>PCA, OPLS-DA</td>
                                    <td>ROC curve</td>
                                    <td>–</td>
                                    <td>2018</td>
                                    <td>30</td>
                                </tr>

                                <tr>
                                    <td>China</td>
                                    <td>29740076</td>
                                    <td>Chen et al. 2018</td>
                                    <td>#3</td>
                                    <td>NSCLC vs. healthy</td>
                                    <td>serum</td>
                                    <td>diagnosis</td>
                                    <td>NSCLC </td>
                                    <td>I, II</td>
                                    <td>90</td>
                                    <td>40, 50</td>
                                    <td> 58.1 ± 9.0</td>
                                    <td>–</td>
                                    <td>healthy</td>
                                    <td>90</td>
                                    <td>42, 48</td>
                                    <td>53.0 ± 11.8</td>
                                    <td>–</td>
                                    <td>GC</td>
                                    <td>EI</td>
                                    <td>–</td>
                                    <td>TOF</td>
                                    <td>–</td>
                                    <td>Chroma TOF</td>
                                    <td>LECO-Fiehn Rtx 5 </td>
                                    <td>PCA, OPLS-DA</td>
                                    <td>ROC curve</td>
                                    <td>–</td>
                                    <td>2018</td>
                                    <td>31</td>
                                </tr>

                                <tr>
                                    <td>China</td>
                                    <td>29740076</td>
                                    <td>Chen et al. 2018</td>
                                    <td>#4</td>
                                    <td>NSCLC vs. healthy</td>
                                    <td>serum</td>
                                    <td>diagnosis</td>
                                    <td>NSCLC </td>
                                    <td>I, II</td>
                                    <td>90</td>
                                    <td>40, 50</td>
                                    <td> 58.1 ± 9.0</td>
                                    <td>–</td>
                                    <td>healthy</td>
                                    <td>90</td>
                                    <td>42, 48</td>
                                    <td>53.0 ± 11.8</td>
                                    <td>–</td>
                                    <td>LC</td>
                                    <td>ESI</td>
                                    <td>both</td>
                                    <td>Q-TOF</td>
                                    <td>–</td>
                                    <td>Analyst TF, XCMS </td>
                                    <td>–</td>
                                    <td> Student’s t-test</td>
                                    <td>ROC curve</td>
                                    <td>–</td>
                                    <td>2018</td>
                                    <td>32</td>
                                </tr>

                                <tr>
                                    <td>US</td>
                                    <td>26282632</td>
                                    <td>Fahrmann et al. 2015</td>
                                    <td>#1</td>
                                    <td>adenocarcinoma vs. healthy</td>
                                    <td>serum</td>
                                    <td>diagnosis</td>
                                    <td>adenocarcinoma</td>
                                    <td>I, II, III, IV</td>
                                    <td>49</td>
                                    <td>17, 32</td>
                                    <td>65.9 ± 9.87</td>
                                    <td>–</td>
                                    <td>healthy</td>
                                    <td>31</td>
                                    <td>11, 20</td>
                                    <td>64.1 ± 8.97</td>
                                    <td>–</td>
                                    <td>GC</td>
                                    <td>EI</td>
                                    <td>–</td>
                                    <td>TOF</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>UC Davis Metabolomics BinBase database</td>
                                    <td>regress (by the covariates: age, gender and smoking history [packs per year]), permutation test</td>
                                    <td>random forest</td>
                                    <td>–</td>
                                    <td>2015</td>
                                    <td>33</td>
                                </tr>

                                <tr>
                                    <td>US</td>
                                    <td>26282632</td>
                                    <td>Fahrmann et al. 2015</td>
                                    <td>#2</td>
                                    <td>adenocarcinoma vs. healthy</td>
                                    <td>serum</td>
                                    <td>diagnosis</td>
                                    <td>adenocarcinoma</td>
                                    <td>I, II, III, IV</td>
                                    <td>43</td>
                                    <td>21, 22</td>
                                    <td>67.3 ± 10.10</td>
                                    <td>–</td>
                                    <td>healthy</td>
                                    <td>43</td>
                                    <td>21, 22</td>
                                    <td>65.9 ± 8.05</td>
                                    <td>–</td>
                                    <td>GC</td>
                                    <td>EI</td>
                                    <td>–</td>
                                    <td>TOF</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>UC Davis Metabolomics BinBase database</td>
                                    <td>regress (by the covariates: age, gender and smoking history [packs per year]), permutation test</td>
                                    <td>random forest</td>
                                    <td>–</td>
                                    <td>2015</td>
                                    <td>34</td>
                                </tr>

                                <tr>
                                    <td>US</td>
                                    <td>26282632</td>
                                    <td>Fahrmann et al. 2015</td>
                                    <td>#3</td>
                                    <td>adenocarcinoma vs. healthy</td>
                                    <td>plasma</td>
                                    <td>diagnosis</td>
                                    <td>adenocarcinoma</td>
                                    <td>I, II, III, IV</td>
                                    <td>52</td>
                                    <td>17, 35</td>
                                    <td>65.9 ± 9.66</td>
                                    <td>–</td>
                                    <td>healthy</td>
                                    <td>31</td>
                                    <td>11, 20</td>
                                    <td>64.1 ± 8.97</td>
                                    <td>–</td>
                                    <td>GC</td>
                                    <td>EI</td>
                                    <td>–</td>
                                    <td>TOF</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>UC Davis Metabolomics BinBase database</td>
                                    <td>regress (by the covariates: age, gender and smoking history [packs per year]), permutation test</td>
                                    <td>random forest</td>
                                    <td>–</td>
                                    <td>2015</td>
                                    <td>35</td>
                                </tr>

                                <tr>
                                    <td>US</td>
                                    <td>26282632</td>
                                    <td>Fahrmann et al. 2015</td>
                                    <td>#4</td>
                                    <td>adenocarcinoma vs. healthy</td>
                                    <td>plasma</td>
                                    <td>diagnosis</td>
                                    <td>adenocarcinoma</td>
                                    <td>I, II, III, IV</td>
                                    <td>43</td>
                                    <td>21, 22</td>
                                    <td>67.3 ± 10.10</td>
                                    <td>–</td>
                                    <td>healthy</td>
                                    <td>43</td>
                                    <td>21, 22</td>
                                    <td>65.9 ± 8.05</td>
                                    <td>–</td>
                                    <td>GC</td>
                                    <td>EI</td>
                                    <td>–</td>
                                    <td>TOF</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>UC Davis Metabolomics BinBase database</td>
                                    <td>regress (by the covariates: age, gender and smoking history [packs per year]), permutation test</td>
                                    <td>random forest</td>
                                    <td>–</td>
                                    <td>2015</td>
                                    <td>36</td>
                                </tr>

                                <tr>
                                    <td>Austria</td>
                                    <td>24862102</td>
                                    <td>Filipiak et al. 2014</td>
                                    <td>#1</td>
                                    <td>small-cell LC + squamous-cell LC + adenocarcinoma + large-cell carcinoma + mesothelioma + carcinoid	vs. healthy</td>
                                    <td>exhaled breath</td>
                                    <td>diagnosis</td>
                                    <td>SCLC, squamous cell carcinoma, adenocarcinoma, large cell carcinoma, mesothelioma, carcinoid	</td>
                                    <td>–</td>
                                    <td>36</td>
                                    <td>25, 11</td>
                                    <td>63 ± 7</td>
                                    <td>former, non-smoker </td>
                                    <td>healthy</td>
                                    <td>28</td>
                                    <td>12, 16</td>
                                    <td>52 ± 17</td>
                                    <td>former, non-smokers</td>
                                    <td>GC</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>NIST 2005</td>
                                    <td>Kruskal–Wallis test, Spearman</td>
                                    <td>Kruskal–Wallis test, Spearman</td>
                                    <td>–</td>
                                    <td>2014</td>
                                    <td>37</td>
                                </tr>

                                <tr>
                                    <td>Austria</td>
                                    <td>24862102</td>
                                    <td>Filipiak et al. 2014</td>
                                    <td>#2</td>
                                    <td>NSCLC + SCLC (tumor tissue) vs. NSCLC + SCLC (normal tissue)</td>
                                    <td>tissue</td>
                                    <td>diagnosis</td>
                                    <td>NSCLC, SCLC</td>
                                    <td>I, II, III, IV</td>
                                    <td>14</td>
                                    <td>6, 8</td>
                                    <td>67.7, 63.4</td>
                                    <td>smoker, non-smoker</td>
                                    <td>tumor vs. adjacent normal tissue</td>
                                    <td>13</td>
                                    <td>12, 16</td>
                                    <td>52 ± 17</td>
                                    <td>former, non-smokers</td>
                                    <td>GC</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>NIST 2005</td>
                                    <td>Kruskal–Wallis test, Spearman</td>
                                    <td>Kruskal–Wallis test, Spearman</td>
                                    <td>–</td>
                                    <td>2014</td>
                                    <td>38</td>
                                </tr>

                                <tr>
                                    <td>Germany</td>
                                    <td>19839051</td>
                                    <td>Fuchs et al. 2010</td>
                                    <td>#1</td>
                                    <td>NSCLC + SCLC vs. healthy</td>
                                    <td>exhaled breath</td>
                                    <td>diagnosis</td>
                                    <td>NSCLC, SCLC</td>
                                    <td>–</td>
                                    <td>12</td>
                                    <td>11, 1</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>healthy</td>
                                    <td>24</td>
                                    <td>10, 14</td>
                                    <td>–</td>
                                    <td>smoker, non-smoker</td>
                                    <td>GC</td>
                                    <td>EI</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>Kruskal–Wallis</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>2010</td>
                                    <td>39</td>
                                </tr>

                                <tr>
                                    <td>Germany</td>
                                    <td>19839051</td>
                                    <td>Fuchs et al. 2010</td>
                                    <td>#2</td>
                                    <td>NSCLC + SCLC vs. healthy</td>
                                    <td>exhaled breath</td>
                                    <td>diagnosis</td>
                                    <td>NSCLC, SCLC</td>
                                    <td>–</td>
                                    <td>12</td>
                                    <td>11, 1</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>healthy</td>
                                    <td>24</td>
                                    <td>10, 14</td>
                                    <td>–</td>
                                    <td>smoker, non-smoker</td>
                                    <td>GC</td>
                                    <td>EI</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>2010</td>
                                    <td>40</td>
                                </tr>

                                <tr>
                                    <td>China</td>
                                    <td>22906735</td>
                                    <td>Guo et al. 2012</td>
                                    <td>#1</td>
                                    <td>adenocarcinoma + squamous cell cancer + small cell carcinoma  vs. healthy </td>
                                    <td>serum</td>
                                    <td>diagnosis</td>
                                    <td>adenocarcinoma, squamous cell carcinoma, SCLC</td>
                                    <td>I, II, III, IV</td>
                                    <td>58</td>
                                    <td>39, 19</td>
                                    <td>52 ± 12 / 52 ± 12</td>
                                    <td>–</td>
                                    <td>healthy</td>
                                    <td>495</td>
                                    <td>251, 244</td>
                                    <td>61 ± 10 / 63 ± 12</td>
                                    <td>–</td>
                                    <td>DI</td>
                                    <td>ESI</td>
                                    <td>positive</td>
                                    <td>FT-ICR</td>
                                    <td>MS/MS </td>
                                    <td>–</td>
                                    <td>HMDB, Lipid maps</td>
                                    <td>PLS-DA, </td>
                                    <td>ROC curve</td>
                                    <td>–</td>
                                    <td>2012</td>
                                    <td>41</td>
                                </tr>

                                <tr>
                                    <td>China</td>
                                    <td>27217771</td>
                                    <td>Huang et al. 2016</td>
                                    <td>#1</td>
                                    <td>lung cancer vs. healthy</td>
                                    <td>dried blood spot</td>
                                    <td>diagnosis</td>
                                    <td>lung cancer</td>
                                    <td>–</td>
                                    <td>222</td>
                                    <td>94, 128</td>
                                    <td>median: 57.47 (27-81)</td>
                                    <td>–</td>
                                    <td>healthy</td>
                                    <td>96</td>
                                    <td>30, 66</td>
                                    <td>median: 56.07 (32-80)</td>
                                    <td>–</td>
                                    <td>LC</td>
                                    <td>ESI</td>
                                    <td>positive</td>
                                    <td>QTrap</td>
                                    <td>MS/MS</td>
                                    <td>Analyst software, ChemoView software</td>
                                    <td>–</td>
                                    <td>PLS-DA, ANOVA, student’s t-test</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>2016</td>
                                    <td>42</td>
                                </tr>

                                <tr>
                                    <td>China</td>
                                    <td>27217771</td>
                                    <td>Huang et al. 2016</td>
                                    <td>#2</td>
                                    <td>benign lung disease vs. healthy</td>
                                    <td>dried blood spot</td>
                                    <td>diagnosis</td>
                                    <td>benign lung disease</td>
                                    <td>–</td>
                                    <td>118</td>
                                    <td>55, 63</td>
                                    <td>median: 59.61 (32-80)</td>
                                    <td>–</td>
                                    <td>healthy</td>
                                    <td>96</td>
                                    <td>30, 66</td>
                                    <td>median: 56.07 (32-80)</td>
                                    <td>–</td>
                                    <td>LC</td>
                                    <td>ESI</td>
                                    <td>positive</td>
                                    <td>QTrap</td>
                                    <td>MS/MS</td>
                                    <td>Analyst software, ChemoView software</td>
                                    <td>–</td>
                                    <td>PLS-DA, ANOVA, student’s t-test</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>2016</td>
                                    <td>43</td>
                                </tr>

                                <tr>
                                    <td>China</td>
                                    <td>31442449</td>
                                    <td>Huang et al. 2019</td>
                                    <td>#1</td>
                                    <td>lung cancer vs. healthy</td>
                                    <td>plasma</td>
                                    <td>diagnosis</td>
                                    <td>lung cancer</td>
                                    <td>–</td>
                                    <td>31</td>
                                    <td>19, 12</td>
                                    <td>28-64</td>
                                    <td>–</td>
                                    <td>healthy</td>
                                    <td>35</td>
                                    <td>24, 11</td>
                                    <td>23-60</td>
                                    <td>–</td>
                                    <td>LC</td>
                                    <td>ESI</td>
                                    <td>negative</td>
                                    <td>Q-Orbitrap</td>
                                    <td>MS/MS</td>
                                    <td>XCMS</td>
                                    <td>OSI-SMMS</td>
                                    <td>OPLS-DA, Mann-Whitney U test</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>2019</td>
                                    <td>44</td>
                                </tr>

                                <tr>
                                    <td>China</td>
                                    <td>31442449</td>
                                    <td>Huang et al. 2019</td>
                                    <td>#2</td>
                                    <td>lung cancer vs. healthy</td>
                                    <td>plasma</td>
                                    <td>diagnosis</td>
                                    <td>lung cancer</td>
                                    <td>–</td>
                                    <td>31</td>
                                    <td>19, 12</td>
                                    <td>28-64</td>
                                    <td>–</td>
                                    <td>healthy</td>
                                    <td>35</td>
                                    <td>24, 11</td>
                                    <td>23-60</td>
                                    <td>–</td>
                                    <td>LC</td>
                                    <td>ESI</td>
                                    <td>positive</td>
                                    <td>Q-Orbitrap</td>
                                    <td>MS/MS</td>
                                    <td>XCMS</td>
                                    <td>OSI-SMMS</td>
                                    <td>OPLS-DA, Mann-Whitney U test</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>2019</td>
                                    <td>45</td>
                                </tr>

                                <tr>
                                    <td>Poland</td>
                                    <td>27597283</td>
                                    <td>Klupczynska et al. 2016a</td>
                                    <td>#1</td>
                                    <td>adenocarcinoma + squamous cell carcinoma vs. healthy</td>
                                    <td>serum</td>
                                    <td>diagnosis</td>
                                    <td>adenocarcinoma, squamous cell carcinoma</td>
                                    <td>I, II, III</td>
                                    <td>90</td>
                                    <td>58, 32</td>
                                    <td>64 (48-86)</td>
                                    <td>current, non-smoker, unknown</td>
                                    <td>healthy</td>
                                    <td>63</td>
                                    <td>41, 22</td>
                                    <td>62 (43-78)</td>
                                    <td>smoker, non-smoker, unknown</td>
                                    <td>LC</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>QTRAP</td>
                                    <td>MS/MS</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>t-test, Welch’s t-test or the Mann-Whitney U test, one-way ANOVA</td>
                                    <td>ROC curve analysis (Monte-Carlo cross validation), discriminant function analysis</td>
                                    <td>–</td>
                                    <td>2016</td>
                                    <td>46</td>
                                </tr>

                                <tr>
                                    <td>Poland</td>
                                    <td>27454081</td>
                                    <td>Klupczynska et al. 2016b</td>
                                    <td>#1</td>
                                    <td>squamous cell carcinoma + adenocarcinoma vs. healthy</td>
                                    <td>serum</td>
                                    <td>diagnosis</td>
                                    <td>adenocarcinoma, squamous cell carcinoma</td>
                                    <td>I, II, III</td>
                                    <td>90</td>
                                    <td>58, 32</td>
                                    <td>64 ± 6.9</td>
                                    <td>smoker, non-smoker, unknown</td>
                                    <td>healthy</td>
                                    <td>62</td>
                                    <td>40, 22</td>
                                    <td>62 ± 8.8</td>
                                    <td>smoker, non-smoker, unknown</td>
                                    <td>LC</td>
                                    <td>ESI</td>
                                    <td>negative</td>
                                    <td>triple quadrupole</td>
                                    <td>MS/MS</td>
                                    <td>Analyst software</td>
                                    <td>–</td>
                                    <td>Mann-Whitney U test</td>
                                    <td>ROC curve analysis </td>
                                    <td>–</td>
                                    <td>2016</td>
                                    <td>47</td>
                                </tr>

                                <tr>
                                    <td>Poland</td>
                                    <td>28168355</td>
                                    <td>Klupczynska et al. 2017</td>
                                    <td>#1</td>
                                    <td>adenocarcinoma + squamous cell carcinoma vs. healthy</td>
                                    <td>serum</td>
                                    <td>diagnosis</td>
                                    <td>adenocarcinoma, squamous cell carcinoma</td>
                                    <td>I, II</td>
                                    <td>50</td>
                                    <td>28, 22</td>
                                    <td>65 (53-86)</td>
                                    <td>–</td>
                                    <td>healthy</td>
                                    <td>25</td>
                                    <td>14, 11</td>
                                    <td>64 (50-78)</td>
                                    <td>–</td>
                                    <td>LC</td>
                                    <td>ESI</td>
                                    <td>positive</td>
                                    <td>Q-Orbitrap</td>
                                    <td>MS/MS </td>
                                    <td>MZmine 2.19 software</td>
                                    <td>In-house library, HMDB, mzCloud</td>
                                    <td>t-test</td>
                                    <td>ROC curve analysis (Monte-Carlo cross validation)</td>
                                    <td>–</td>
                                    <td>2017</td>
                                    <td>48</td>
                                </tr>

                                <tr>
                                    <td>Poland</td>
                                    <td>31264112</td>
                                    <td>Klupczynska et al. 2019</td>
                                    <td>#1</td>
                                    <td>adenocarcinoma + squamous cell carcinoma vs. noncancerous lung diseases</td>
                                    <td>serum</td>
                                    <td>diagnosis</td>
                                    <td>adenocarcinoma, squamous cell carcinoma</td>
                                    <td>I</td>
                                    <td>20</td>
                                    <td>11, 9</td>
                                    <td>62 ± 5</td>
                                    <td>smoker, non-smoker</td>
                                    <td>noncancerous lung diseases</td>
                                    <td>20</td>
                                    <td>8, 16</td>
                                    <td>63 ± 6</td>
                                    <td>smoker, non-smoker</td>
                                    <td>flow infusion</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>QTRAP</td>
                                    <td>MS/MS</td>
                                    <td>Analyst</td>
                                    <td>–</td>
                                    <td>Wilcoxon rank-sum test</td>
                                    <td>ROC analysis</td>
                                    <td>–</td>
                                    <td>2019</td>
                                    <td>49</td>
                                </tr>

                                <tr>
                                    <td>China</td>
                                    <td>25117182</td>
                                    <td>Lam et al. 2014</td>
                                    <td>#1</td>
                                    <td>NSCLC + SCLC + anaplastic carcinoma + with atypical cells vs. pulmonary tuberculosis</td>
                                    <td>pleural effusion</td>
                                    <td>diagnosis</td>
                                    <td>NSCLC, SCLC, anaplastic carcinoma</td>
                                    <td>–</td>
                                    <td>32</td>
                                    <td>13, 19</td>
                                    <td>72.8 ± 11.4</td>
                                    <td>smoker, non-smoker</td>
                                    <td> pulmonary tuberculosis</td>
                                    <td>18</td>
                                    <td>10, 8</td>
                                    <td>59.7 ± 25.2 </td>
                                    <td>smoker, non-smoker</td>
                                    <td>LC</td>
                                    <td>ESI</td>
                                    <td>both</td>
                                    <td>TripleTOF</td>
                                    <td>MS/MS</td>
                                    <td>PeakView, LipidView (AB SCIEX),  XCMS</td>
                                    <td>HMDB</td>
                                    <td>t-test, OPLS-DA</td>
                                    <td>ROC curve analysis </td>
                                    <td>–</td>
                                    <td>2014</td>
                                    <td>50</td>
                                </tr>

                                <tr>
                                    <td>China</td>
                                    <td>24856296</td>
                                    <td>Li et al. 2014</td>
                                    <td>#1</td>
                                    <td>SCLC + NSCLC vs. healthy</td>
                                    <td>serum</td>
                                    <td>diagnosis</td>
                                    <td>SCLC, NSCLC</td>
                                    <td>–</td>
                                    <td>23</td>
                                    <td>12, 11</td>
                                    <td>63.0 ± 9.8 / 59.4 ± 5.8</td>
                                    <td>–</td>
                                    <td>healthy</td>
                                    <td>23</td>
                                    <td>11, 12</td>
                                    <td>51.0 ± 11.1 / 56.3 ± 14.3</td>
                                    <td>–</td>
                                    <td>LC</td>
                                    <td>–</td>
                                    <td>positive</td>
                                    <td>Q-TOF</td>
                                    <td>MS/MS</td>
                                    <td>MarkerLynx</td>
                                    <td>METLIN, HMDB, KEGG</td>
                                    <td>PCA, PLS-DA, OSC-PLS-DA, student’s t-test</td>
                                    <td>ROC curve analysis </td>
                                    <td>–</td>
                                    <td>2014</td>
                                    <td>51</td>
                                </tr>

                                <tr>
                                    <td>China</td>
                                    <td>24856296</td>
                                    <td>Li et al. 2014</td>
                                    <td>#2</td>
                                    <td>SCLC + NSCLC vs. healthy</td>
                                    <td>serum</td>
                                    <td>diagnosis</td>
                                    <td>SCLC, NSCLC</td>
                                    <td>–</td>
                                    <td>23</td>
                                    <td>12, 11</td>
                                    <td>63.0 ± 9.8 / 59.4 ± 5.8</td>
                                    <td>–</td>
                                    <td>healthy</td>
                                    <td>23</td>
                                    <td>11, 12</td>
                                    <td>51.0 ± 11.1 / 56.3 ± 14.3</td>
                                    <td>–</td>
                                    <td>LC</td>
                                    <td>–</td>
                                    <td>negative</td>
                                    <td>Q-TOF</td>
                                    <td>MS/MS</td>
                                    <td>MarkerLynx</td>
                                    <td>METLIN, HMDB, KEGG</td>
                                    <td>PCA, PLS-DA, OSC-PLS-DA, student’s t-test</td>
                                    <td>ROC curve analysis </td>
                                    <td>–</td>
                                    <td>2014</td>
                                    <td>52</td>
                                </tr>

                                <tr>
                                    <td>China</td>
                                    <td>24856296</td>
                                    <td>Li et al. 2014</td>
                                    <td>#3</td>
                                    <td>SCLC + NSCLC vs. healthy</td>
                                    <td>serum</td>
                                    <td>diagnosis</td>
                                    <td>SCLC, NSCLC</td>
                                    <td>–</td>
                                    <td>23</td>
                                    <td>12, 11</td>
                                    <td>63.0 ± 9.8 / 59.4 ± 5.8</td>
                                    <td>–</td>
                                    <td>healthy</td>
                                    <td>23</td>
                                    <td>11, 12</td>
                                    <td>51.0 ± 11.1 / 56.3 ± 14.3</td>
                                    <td>–</td>
                                    <td>LC</td>
                                    <td>–</td>
                                    <td>both</td>
                                    <td>Q-TOF</td>
                                    <td>MS/MS</td>
                                    <td>MarkerLynx</td>
                                    <td>METLIN, HMDB, KEGG</td>
                                    <td>PCA, PLS-DA, OSC-PLS-DA, student’s t-test</td>
                                    <td>ROC curve analysis </td>
                                    <td>–</td>
                                    <td>2014</td>
                                    <td>53</td>
                                </tr>

                                <tr>
                                    <td>US</td>
                                    <td>26233567</td>
                                    <td>Li et al. 2015</td>
                                    <td>#1</td>
                                    <td>lung cancer vs. healthy</td>
                                    <td>exhaled breath</td>
                                    <td>diagnosis</td>
                                    <td>lung cancer</td>
                                    <td>I, II, III, IV</td>
                                    <td>85</td>
                                    <td>46, 39</td>
                                    <td>66.12 ± 10.1</td>
                                    <td>former, current, non-smoker</td>
                                    <td>healthy</td>
                                    <td>85</td>
                                    <td>43, 42</td>
                                    <td>42.15 ± 14.2</td>
                                    <td>current, non-smoker</td>
                                    <td>DI</td>
                                    <td>nano-ESI</td>
                                    <td>–</td>
                                    <td>LTQ-FT-ICR</td>
                                    <td>MS/MS</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>Kruskal-Wallis test</td>
                                    <td>ROC curve</td>
                                    <td>–</td>
                                    <td>2015</td>
                                    <td>54</td>
                                </tr>

                                <tr>
                                    <td>US</td>
                                    <td>26233567</td>
                                    <td>Li et al. 2015</td>
                                    <td>#2</td>
                                    <td>lung cancer vs. healthy smoker</td>
                                    <td>exhaled breath</td>
                                    <td>diagnosis</td>
                                    <td>lung cancer</td>
                                    <td>I, II, III, IV</td>
                                    <td>85</td>
                                    <td>46, 39</td>
                                    <td>66.12 ± 10.1</td>
                                    <td>former, current, non-smoker</td>
                                    <td>healthy</td>
                                    <td>45</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>current</td>
                                    <td>DI</td>
                                    <td>nano-ESI</td>
                                    <td>–</td>
                                    <td>LTQ-FT-ICR</td>
                                    <td>MS/MS</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>Kruskal-Wallis test</td>
                                    <td>ROC curve</td>
                                    <td>–</td>
                                    <td>2015</td>
                                    <td>55</td>
                                </tr>

                                <tr>
                                    <td>US</td>
                                    <td>26233567</td>
                                    <td>Li et al. 2015</td>
                                    <td>#3</td>
                                    <td>lung cancer vs. healthy nonsmoker</td>
                                    <td>exhaled breath</td>
                                    <td>diagnosis</td>
                                    <td>lung cancer</td>
                                    <td>I, II, III, IV</td>
                                    <td>85</td>
                                    <td>46, 39</td>
                                    <td>66.12 ± 10.1</td>
                                    <td>former, current, non-smoker</td>
                                    <td>healthy</td>
                                    <td>40</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>non-smoker</td>
                                    <td>DI</td>
                                    <td>nano-ESI</td>
                                    <td>–</td>
                                    <td>LTQ-FT-ICR</td>
                                    <td>MS/MS</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>Kruskal-Wallis test</td>
                                    <td>ROC curve</td>
                                    <td>–</td>
                                    <td>2015</td>
                                    <td>56</td>
                                </tr>

                                <tr>
                                    <td>China</td>
                                    <td>26404114</td>
                                    <td>Li et al. 2015</td>
                                    <td>#1</td>
                                    <td> adenocarcinoma + squamous cell lung carcinoma (tumor tissue) vs. adenocarcinoma + squamous cell lung carcinoma (normal tissue)</td>
                                    <td>tissue</td>
                                    <td>diagnosis</td>
                                    <td>adenocarcinoma, squamous cell carcinoma</td>
                                    <td>–</td>
                                    <td>52</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>tumor vs. adjacent normal tissue</td>
                                    <td>21</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>LC</td>
                                    <td>AFADESI</td>
                                    <td>both</td>
                                    <td>Q-Orbitrap, Q-TOF</td>
                                    <td>MS/MS</td>
                                    <td>Markerview (AB SCIEX)</td>
                                    <td>LIPID MAPS, Massbank, HMDB, METLIN</td>
                                    <td>t-test, PLS-DA, OPLS-DA</td>
                                    <td>ROC curve analysis </td>
                                    <td>–</td>
                                    <td>2015</td>
                                    <td>57</td>
                                </tr>

                                <tr>
                                    <td>Austria</td>
                                    <td>19397483</td>
                                    <td>Ligor et al. 2009</td>
                                    <td>#1</td>
                                    <td>small cell + non-small cell + mesothelioma + carcinoid vs. healthy</td>
                                    <td>exhaled breath</td>
                                    <td>diagnosis</td>
                                    <td>SCLC, NSCLC, mesothelioma, carcinoid</td>
                                    <td>–</td>
                                    <td>65</td>
                                    <td>41, 24</td>
                                    <td>–</td>
                                    <td>former, current, non-smoker</td>
                                    <td>healthy</td>
                                    <td>31</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>former, current, non-smoker</td>
                                    <td>GC</td>
                                    <td>EI</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>NIST 2005</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>2009</td>
                                    <td>58</td>
                                </tr>

                                <tr>
                                    <td>China</td>
                                    <td>24321761</td>
                                    <td>Liu et al. 2014</td>
                                    <td>#1</td>
                                    <td>NSCLC + SCLC vs. tuberculous pleurisy + pneumonia</td>
                                    <td>pleural effusion</td>
                                    <td>diagnosis</td>
                                    <td>NSCLC, SCLC</td>
                                    <td>–</td>
                                    <td>20</td>
                                    <td>16, 4</td>
                                    <td>73 (53-85)</td>
                                    <td>–</td>
                                    <td>tuberculous pleurisy, pneumonia</td>
                                    <td>20</td>
                                    <td>14, 6</td>
                                    <td>63.6 (44-86)</td>
                                    <td>–</td>
                                    <td>GC</td>
                                    <td>EI</td>
                                    <td>positive</td>
                                    <td>single quad</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>NIST02 library </td>
                                    <td>Student&#x27;s t-test, corrected t-test</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>2014</td>
                                    <td>59</td>
                                </tr>

                                <tr>
                                    <td>Russia</td>
                                    <td>23212094</td>
                                    <td>Lokhov et al. 2012</td>
                                    <td>#1</td>
                                    <td>lung cancer vs. healthy</td>
                                    <td>plasma</td>
                                    <td>diagnosis</td>
                                    <td>lung cancer</td>
                                    <td>I, II, III, IV</td>
                                    <td>100</td>
                                    <td>88, 12</td>
                                    <td>median: 60 (44-76)</td>
                                    <td>smoker, non-smoker</td>
                                    <td>healthy</td>
                                    <td>100</td>
                                    <td>89, 11</td>
                                    <td>median: 59 (37-71)</td>
                                    <td>smoker, non-smoker</td>
                                    <td>DI</td>
                                    <td>ESI</td>
                                    <td>both</td>
                                    <td>Q-TOF</td>
                                    <td>–</td>
                                    <td>DataAnalysis </td>
                                    <td>Human Metabolome Database, Metlin Database, NIST Chemistry WebBook Database</td>
                                    <td>odds ratio</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>2012</td>
                                    <td>60</td>
                                </tr>

                                <tr>
                                    <td>Japan</td>
                                    <td>21176209</td>
                                    <td>Maeda et al. 2010</td>
                                    <td>#1</td>
                                    <td>NSCLC vs. healthy</td>
                                    <td>plasma</td>
                                    <td>–</td>
                                    <td>NSCLC</td>
                                    <td>I, II, III, IV</td>
                                    <td>141</td>
                                    <td>93, 48</td>
                                    <td>62.7 ± 9.2</td>
                                    <td>former, current, non-smoker </td>
                                    <td>healthy</td>
                                    <td>423</td>
                                    <td>279, 144</td>
                                    <td>61.1 ± 8.7</td>
                                    <td>former, current, non-smoker</td>
                                    <td>LC</td>
                                    <td>ESI</td>
                                    <td>positive </td>
                                    <td>quadrupole</td>
                                    <td>–</td>
                                    <td>Xcalibur </td>
                                    <td>–</td>
                                    <td> Mann-Whitney U-test, PCA</td>
                                    <td>ROC curve</td>
                                    <td>–</td>
                                    <td>2010</td>
                                    <td>61</td>
                                </tr>

                                <tr>
                                    <td>US</td>
                                    <td>24736543</td>
                                    <td>Mathe et al. 2014</td>
                                    <td>#1</td>
                                    <td>NSCLC vs. healthy</td>
                                    <td>urine</td>
                                    <td>diagnosis, prognosis</td>
                                    <td>NSCLC</td>
                                    <td>I, II, III, IV</td>
                                    <td>469</td>
                                    <td>237, 232</td>
                                    <td>66,2</td>
                                    <td>smoker, non-smoker</td>
                                    <td>healthy</td>
                                    <td>536</td>
                                    <td>276, 260</td>
                                    <td>66,6</td>
                                    <td>–</td>
                                    <td>LC</td>
                                    <td>ESI</td>
                                    <td>–</td>
                                    <td>Q-TOF</td>
                                    <td>MS/MS</td>
                                    <td>R package XCMS </td>
                                    <td>METLIN, HMDB </td>
                                    <td>Non-parametric Wilcoxon test</td>
                                    <td>random forest</td>
                                    <td>Cox proportional hazards regression</td>
                                    <td>2014</td>
                                    <td>62</td>
                                </tr>

                                <tr>
                                    <td>US</td>
                                    <td>26762741</td>
                                    <td>Mazzone et al. 2016</td>
                                    <td>#1</td>
                                    <td>adenocarcinoma + squamous cell carcinoma vs. at-risk controls </td>
                                    <td>serum</td>
                                    <td>–</td>
                                    <td>adenocarcinoma, squamous cell carcinoma</td>
                                    <td>I, II, III</td>
                                    <td>94</td>
                                    <td>52, 42</td>
                                    <td>68,7</td>
                                    <td>–</td>
                                    <td>at-risk controls </td>
                                    <td>190</td>
                                    <td>96, 94</td>
                                    <td>66,2</td>
                                    <td>–</td>
                                    <td>GC</td>
                                    <td>EI</td>
                                    <td>–</td>
                                    <td>quadrupole</td>
                                    <td>MS/MS</td>
                                    <td> Metabolon LIMS system</td>
                                    <td> Metabolon LIMS system</td>
                                    <td>two- sample independent t test </td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>2016</td>
                                    <td>63</td>
                                </tr>

                                <tr>
                                    <td>US</td>
                                    <td>26762741</td>
                                    <td>Mazzone et al. 2016</td>
                                    <td>#2</td>
                                    <td>adenocarcinoma + squamous cell carcinoma vs. at-risk controls </td>
                                    <td>serum</td>
                                    <td>–</td>
                                    <td>adenocarcinoma, squamous cell carcinoma</td>
                                    <td>I, II, III</td>
                                    <td>94</td>
                                    <td>52, 42</td>
                                    <td>68,7</td>
                                    <td>–</td>
                                    <td>at-risk controls </td>
                                    <td>190</td>
                                    <td>96, 94</td>
                                    <td>66,2</td>
                                    <td>–</td>
                                    <td>LC</td>
                                    <td>ESI</td>
                                    <td>positive</td>
                                    <td>linear ion-trap</td>
                                    <td>MS/MS</td>
                                    <td> Metabolon LIMS system</td>
                                    <td> Metabolon LIMS system</td>
                                    <td>two- sample independent t test </td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>2016</td>
                                    <td>64</td>
                                </tr>

                                <tr>
                                    <td>US</td>
                                    <td>26762741</td>
                                    <td>Mazzone et al. 2016</td>
                                    <td>#3</td>
                                    <td>adenocarcinoma + squamous cell carcinoma vs. at-risk controls </td>
                                    <td>serum</td>
                                    <td>–</td>
                                    <td>adenocarcinoma, squamous cell carcinoma</td>
                                    <td>I, II, III</td>
                                    <td>94</td>
                                    <td>52, 42</td>
                                    <td>68,7</td>
                                    <td>–</td>
                                    <td>at-risk controls </td>
                                    <td>190</td>
                                    <td>96, 94</td>
                                    <td>66,2</td>
                                    <td>–</td>
                                    <td>LC</td>
                                    <td>ESI</td>
                                    <td>negative</td>
                                    <td>linear ion-trap</td>
                                    <td>MS/MS</td>
                                    <td> Metabolon LIMS system</td>
                                    <td> Metabolon LIMS system</td>
                                    <td>two- sample independent t test </td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>2016</td>
                                    <td>65</td>
                                </tr>

                                <tr>
                                    <td>US</td>
                                    <td>25859693</td>
                                    <td>Miyamoto et al. 2015</td>
                                    <td>#1</td>
                                    <td>adenocarcinoma vs. healthy</td>
                                    <td>blood</td>
                                    <td>diagnosis</td>
                                    <td>adenocarcinoma</td>
                                    <td>unknown (mostly late stage)</td>
                                    <td>18</td>
                                    <td>10, 8</td>
                                    <td>67 (50-85) / 62 (53-72)</td>
                                    <td>former, current</td>
                                    <td>healthy</td>
                                    <td>20</td>
                                    <td>8, 12</td>
                                    <td>64 (49-80) / 66 (58-82)</td>
                                    <td>former, current</td>
                                    <td>GC</td>
                                    <td>EI</td>
                                    <td>–</td>
                                    <td>TOF</td>
                                    <td>MS/MS</td>
                                    <td>ChromaTOF software (Leco)</td>
                                    <td>UC Davis Metabolomics BinBase database</td>
                                    <td>Analysis of Covariance</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>2015</td>
                                    <td>66</td>
                                </tr>

                                <tr>
                                    <td>US</td>
                                    <td>25859693</td>
                                    <td>Miyamoto et al. 2015</td>
                                    <td>#2</td>
                                    <td>NSCLC + SCLC + mesothelioma + secondary metastasis to lung + other vs. healthy</td>
                                    <td>blood</td>
                                    <td>diagnosis</td>
                                    <td>NSCLC, SCLC, mesothelioma, secondary metastasis to lung</td>
                                    <td>I, II, III, IV</td>
                                    <td>11</td>
                                    <td>4, 7</td>
                                    <td>67 (61-73) / 67 (47-76)</td>
                                    <td>smoker, non-smoker</td>
                                    <td>healthy</td>
                                    <td>11</td>
                                    <td>5, 6</td>
                                    <td>69 (61-83) / 54 (44-61)</td>
                                    <td>unknown</td>
                                    <td>GC</td>
                                    <td>EI</td>
                                    <td>–</td>
                                    <td>TOF</td>
                                    <td>MS/MS</td>
                                    <td>ChromaTOF software (Leco)</td>
                                    <td>UC Davis Metabolomics BinBase database</td>
                                    <td>Analysis of Covariance</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>2015</td>
                                    <td>67</td>
                                </tr>

                                <tr>
                                    <td>Spain</td>
                                    <td>30099851</td>
                                    <td>Moreno et al. 2018</td>
                                    <td>#1</td>
                                    <td>adenocarcinoma (tumor tissue) vs. adenocarcinoma (normal tissue)</td>
                                    <td>tissue</td>
                                    <td>therapy, diagnosis</td>
                                    <td>adenocarcinoma</td>
                                    <td>I, II, III</td>
                                    <td>33</td>
                                    <td>24, 9</td>
                                    <td>62.11 ± 9.73</td>
                                    <td>–</td>
                                    <td>tumor vs. adjacent normal tissue</td>
                                    <td>33</td>
                                    <td>24, 9</td>
                                    <td>62.11 ± 9.73</td>
                                    <td>–</td>
                                    <td>LC, GC</td>
                                    <td>ESI, EI</td>
                                    <td>both</td>
                                    <td>LC: linear ion-trap, GC: single-quadrupole </td>
                                    <td>LC: MS/MS </td>
                                    <td>–</td>
                                    <td>KEGG, HMDB</td>
                                    <td>paired two-sample t-test, PLS-DA</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>2018</td>
                                    <td>68</td>
                                </tr>

                                <tr>
                                    <td>Spain</td>
                                    <td>30099851</td>
                                    <td>Moreno et al. 2018</td>
                                    <td>#2</td>
                                    <td>squamous cell lung carcinoma (tumor tissue) vs. squamous cell lung carcinoma (normal tissue)</td>
                                    <td>tissue</td>
                                    <td>therapy, diagnosis</td>
                                    <td>squamous cell carcinoma</td>
                                    <td>I, II, III</td>
                                    <td>35</td>
                                    <td>35, 0</td>
                                    <td>68.71 ± 7.46</td>
                                    <td>–</td>
                                    <td>tumor vs. adjacent normal tissue</td>
                                    <td>35</td>
                                    <td>35, 0</td>
                                    <td>68.71 ± 7.46</td>
                                    <td>–</td>
                                    <td>LC, GC</td>
                                    <td>ESI, EI</td>
                                    <td>both</td>
                                    <td>LC: linear ion-trap, GC: single-quadrupole </td>
                                    <td>LC: MS/MS </td>
                                    <td>–</td>
                                    <td>KEGG, HMDB</td>
                                    <td>paired two-sample t-test, PLS-DA</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>2018</td>
                                    <td>69</td>
                                </tr>

                                <tr>
                                    <td>China</td>
                                    <td>30892048</td>
                                    <td>Mu et al. 2019</td>
                                    <td>#1</td>
                                    <td>NSCLC vs. healthy</td>
                                    <td>serum</td>
                                    <td>diagnosis</td>
                                    <td>NSCLC</td>
                                    <td>I, II, III, IV</td>
                                    <td>30</td>
                                    <td>0, 30</td>
                                    <td>60.4 ± 9.7</td>
                                    <td>non-smoker</td>
                                    <td>healthy</td>
                                    <td>30</td>
                                    <td>0, 30</td>
                                    <td>54.7 ± 14.3</td>
                                    <td>non-smoker</td>
                                    <td>GC</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>PCA, PLS-DA, Mann-Whitney U test</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>2019</td>
                                    <td>70</td>
                                </tr>

                                <tr>
                                    <td>China</td>
                                    <td>31222099</td>
                                    <td>Muranishi et al. 2019</td>
                                    <td>#1</td>
                                    <td>adenocarcinoma (tumor vs. adjacent normal tissue)</td>
                                    <td>tissue</td>
                                    <td>diagnosis</td>
                                    <td>adenocarcinoma</td>
                                    <td>I</td>
                                    <td>25</td>
                                    <td>–</td>
                                    <td>46-82</td>
                                    <td>–</td>
                                    <td>tumor vs. adjacent normal tissue</td>
                                    <td>25</td>
                                    <td>–</td>
                                    <td>46-82</td>
                                    <td>–</td>
                                    <td>LC</td>
                                    <td>ESI</td>
                                    <td>positive</td>
                                    <td>Q-TOF</td>
                                    <td>MS/MS</td>
                                    <td>Progenesis QI</td>
                                    <td>LIPID MAPS, HMDB</td>
                                    <td>Student&#x27;s t test</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>2019</td>
                                    <td>71</td>
                                </tr>

                                <tr>
                                    <td>US</td>
                                    <td>15494133</td>
                                    <td>Murphey et al. 2004</td>
                                    <td>#1</td>
                                    <td>NSCLC vs. healthy</td>
                                    <td>urine</td>
                                    <td>therapy</td>
                                    <td>NSCLC</td>
                                    <td>–</td>
                                    <td>19</td>
                                    <td>10, 9</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>healthy</td>
                                    <td>37</td>
                                    <td>20, 17</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>LC</td>
                                    <td>ESI</td>
                                    <td>negative</td>
                                    <td>triple quadrupole</td>
                                    <td>MS/MS</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>Student’s t test, Wilcoxon signed ranks test, ANOVA</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>2004</td>
                                    <td>72</td>
                                </tr>

                                <tr>
                                    <td>Pakistan</td>
                                    <td>25712604</td>
                                    <td>Musharraf et al. 2015</td>
                                    <td>#1</td>
                                    <td>adenocarcinoma + squamous cell cancer + small cell carcinoma + NSCLC vs. healthy + COPD</td>
                                    <td>plasma</td>
                                    <td>–</td>
                                    <td>adenocarcinoma, squamous cell carcinoma, SCLC, NSCLC, lung cancer</td>
                                    <td>I, II, III</td>
                                    <td>96</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>healthy</td>
                                    <td>384</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>GC</td>
                                    <td>EI</td>
                                    <td>–</td>
                                    <td>triple quadrupole</td>
                                    <td>–</td>
                                    <td>Agilent Mass Hunter Qualitative Analysis,  Mass Hunter</td>
                                    <td>Wiley registry NIST 11,  Fiehn RTL libraries</td>
                                    <td>one way ANOVA, Turkey’s honest Significance Difference</td>
                                    <td>Hierarchical clustering, Partial Least Square Discrimination</td>
                                    <td>–</td>
                                    <td>2015</td>
                                    <td>73</td>
                                </tr>

                                <tr>
                                    <td>China</td>
                                    <td>27129889</td>
                                    <td>Ni et al. 2016</td>
                                    <td>#1</td>
                                    <td>lung cancer vs. healthy</td>
                                    <td>serum</td>
                                    <td>diagnosis</td>
                                    <td>lung cancer</td>
                                    <td>–</td>
                                    <td>40</td>
                                    <td>14, 26</td>
                                    <td>67</td>
                                    <td>–</td>
                                    <td>healthy</td>
                                    <td>100</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>LC</td>
                                    <td>ESI</td>
                                    <td>positive</td>
                                    <td>triple quadrupole</td>
                                    <td>MS/MS</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>one-way ANOVA</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>2016</td>
                                    <td>74</td>
                                </tr>

                                <tr>
                                    <td>China</td>
                                    <td>31258653</td>
                                    <td>Ni et al. 2019</td>
                                    <td>#1</td>
                                    <td>lung cancer vs. healthy</td>
                                    <td>serum</td>
                                    <td>diagnosis</td>
                                    <td>lung cancer</td>
                                    <td>–</td>
                                    <td>40</td>
                                    <td>26, 14</td>
                                    <td>66.7 (49-83)</td>
                                    <td>–</td>
                                    <td>healthy</td>
                                    <td>100</td>
                                    <td>65, 35</td>
                                    <td>64.1 (41-90)</td>
                                    <td>–</td>
                                    <td>LC</td>
                                    <td>ESI</td>
                                    <td>positive</td>
                                    <td>triple quadrupole</td>
                                    <td>MS/MS</td>
                                    <td>–</td>
                                    <td>HMDB, KEGG, SMPDB</td>
                                    <td>Mann-Whitney U test, Student&#x27;s t-test, Welch&#x27;s F test </td>
                                    <td>ROC analysis</td>
                                    <td>–</td>
                                    <td>2019</td>
                                    <td>75</td>
                                </tr>

                                <tr>
                                    <td>China</td>
                                    <td>31258653</td>
                                    <td>Ni et al. 2019</td>
                                    <td>#2</td>
                                    <td>NSCLC + SCLC vs. healthy</td>
                                    <td>serum</td>
                                    <td>diagnosis</td>
                                    <td>NSCLC, SCLC</td>
                                    <td>II, III, IV</td>
                                    <td>17</td>
                                    <td>13, 4</td>
                                    <td>66.3 (53-77)</td>
                                    <td>former, current, non-smoker</td>
                                    <td>healthy</td>
                                    <td>30</td>
                                    <td>23, 7</td>
                                    <td>62.8 (34-85)</td>
                                    <td>former, current, non-smoker</td>
                                    <td>LC</td>
                                    <td>ESI</td>
                                    <td>positive</td>
                                    <td>triple quadrupole</td>
                                    <td>MS/MS</td>
                                    <td>–</td>
                                    <td>HMDB, KEGG, SMPDB</td>
                                    <td>Mann-Whitney U test, Student&#x27;s t-test, Welch&#x27;s F test </td>
                                    <td>ROC analysis</td>
                                    <td>–</td>
                                    <td>2019</td>
                                    <td>76</td>
                                </tr>

                                <tr>
                                    <td>UK</td>
                                    <td>27423423</td>
                                    <td>O&#x27;Shea et al. 2016</td>
                                    <td>#1</td>
                                    <td>SCLC + NSCLC + radiological  vs. healthy</td>
                                    <td>sputum</td>
                                    <td>diagnosis</td>
                                    <td>SCLC, NSCLC, radiological</td>
                                    <td>–</td>
                                    <td>23</td>
                                    <td>11, 12</td>
                                    <td>66.6 ± 8.1</td>
                                    <td>former, current, non-smoker </td>
                                    <td>healthy</td>
                                    <td>33</td>
                                    <td>20, 13</td>
                                    <td>55.3 ± 14.6</td>
                                    <td>former, current</td>
                                    <td>flow infusion</td>
                                    <td>ESI</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>PCA, 50–50 MANOVA test, </td>
                                    <td>ROC curve</td>
                                    <td>–</td>
                                    <td>2016</td>
                                    <td>77</td>
                                </tr>

                                <tr>
                                    <td>US</td>
                                    <td>29290988</td>
                                    <td>Peng et al. 2017</td>
                                    <td>#1</td>
                                    <td>NSCLC vs. healthy</td>
                                    <td>tissue</td>
                                    <td>diagnosis</td>
                                    <td>NSCLC</td>
                                    <td>–</td>
                                    <td>18</td>
                                    <td>0, 18</td>
                                    <td>–</td>
                                    <td>smoker, non-smoker</td>
                                    <td>healthy</td>
                                    <td>17</td>
                                    <td>0, 17</td>
                                    <td>–</td>
                                    <td>smoker, non-smoker</td>
                                    <td>LC</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>triple quadrupole</td>
                                    <td>MS/MS</td>
                                    <td> Xcalibur</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>2017</td>
                                    <td>78</td>
                                </tr>

                                <tr>
                                    <td>US</td>
                                    <td>29290988</td>
                                    <td>Peng et al. 2017</td>
                                    <td>#2</td>
                                    <td>NSCLC vs. healthy</td>
                                    <td>tissue</td>
                                    <td>diagnosis</td>
                                    <td>NSCLC</td>
                                    <td>–</td>
                                    <td>17</td>
                                    <td>17, 0</td>
                                    <td>–</td>
                                    <td>smoker, non-smoker</td>
                                    <td>healthy</td>
                                    <td>15</td>
                                    <td>15, 0</td>
                                    <td>–</td>
                                    <td>smoker, non-smoker</td>
                                    <td>LC</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>triple quadrupole</td>
                                    <td>MS/MS</td>
                                    <td> Xcalibur</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>2017</td>
                                    <td>79</td>
                                </tr>

                                <tr>
                                    <td>Spain</td>
                                    <td>26866403</td>
                                    <td>Peralbo-Molina et al. 2016</td>
                                    <td>#1</td>
                                    <td>squamous cell carcinoma + adenocarcinoma + small cell carcinoma + large cell carcinoma + non-small cell lung cancer vs. healthy</td>
                                    <td>exhaled breath</td>
                                    <td>diagnosis</td>
                                    <td>squamous cell carcinoma, adenocarcinoma, large cell carcinoma, NSCLC, SCLC</td>
                                    <td>–</td>
                                    <td>48</td>
                                    <td>45, 3</td>
                                    <td>63 ± 7 </td>
                                    <td>–</td>
                                    <td>healthy</td>
                                    <td>61</td>
                                    <td>53, 8</td>
                                    <td>60  ±  9</td>
                                    <td>non-smoker</td>
                                    <td>GC</td>
                                    <td>EI</td>
                                    <td>–</td>
                                    <td>Q-TOF</td>
                                    <td>–</td>
                                    <td> Mass Profiler Professional (Angilent), Quantitative Analysis (Angilent)</td>
                                    <td>NIST 11, KEGG </td>
                                    <td>unpaired t-test, Fisher&#x27;s exact, Mann–Whitney tests</td>
                                    <td>Support-vector machine, ROC curve analysis </td>
                                    <td>–</td>
                                    <td>2016</td>
                                    <td>80</td>
                                </tr>

                                <tr>
                                    <td>Spain</td>
                                    <td>26866403</td>
                                    <td>Peralbo-Molina et al. 2016</td>
                                    <td>#2</td>
                                    <td>squamous cell carcinoma + adenocarcinoma + small cell carcinoma + large cell carcinoma + non-small cell lung cancer vs. risk factor</td>
                                    <td>exhaled breath</td>
                                    <td>diagnosis</td>
                                    <td>squamous cell carcinoma, adenocarcinoma, large cell carcinoma, NSCLC, SCLC</td>
                                    <td>–</td>
                                    <td>48</td>
                                    <td>45, 3</td>
                                    <td>63 ± 7 </td>
                                    <td>–</td>
                                    <td>at-risk controls</td>
                                    <td>130</td>
                                    <td>107, 23</td>
                                    <td>61±8</td>
                                    <td>former, active smokers</td>
                                    <td>GC</td>
                                    <td>EI</td>
                                    <td>–</td>
                                    <td>Q-TOF</td>
                                    <td>–</td>
                                    <td> Mass Profiler Professional (Angilent), Quantitative Analysis (Angilent)</td>
                                    <td>NIST 11, KEGG </td>
                                    <td>unpaired t-test, Fisher&#x27;s exact, Mann–Whitney tests</td>
                                    <td>Support-vector machine, ROC curve analysis </td>
                                    <td>–</td>
                                    <td>2016</td>
                                    <td>81</td>
                                </tr>

                                <tr>
                                    <td>Poland</td>
                                    <td>28803255</td>
                                    <td>Ro?-Mazurczyk et al. 2017</td>
                                    <td>#1</td>
                                    <td>adenocarcinoma +  squamous cell carcinoma vs. healthy</td>
                                    <td>serum</td>
                                    <td>diagnosis</td>
                                    <td>adenocarcinoma, squamous cell carcinoma</td>
                                    <td>I, II, III</td>
                                    <td>31</td>
                                    <td>17, 14</td>
                                    <td>52-72</td>
                                    <td>–</td>
                                    <td>healthy</td>
                                    <td>92</td>
                                    <td>52, 40</td>
                                    <td>52–73 </td>
                                    <td>–</td>
                                    <td>GC</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>TOF</td>
                                    <td>In-source fragmentation</td>
                                    <td>Leco ChromaTOF-GC</td>
                                    <td> Replib, Mainlib and Fiehn libraries</td>
                                    <td>two-sample T test, U Mann-Whitney test, Benjamini-Hochberg approach</td>
                                    <td>ROC curve</td>
                                    <td>–</td>
                                    <td>2017</td>
                                    <td>82</td>
                                </tr>

                                <tr>
                                    <td>US</td>
                                    <td>30104001</td>
                                    <td>Sappington et al. 2018</td>
                                    <td>#1</td>
                                    <td>adenocarcinoma + squamous cell carcinoma vs. non-malignant</td>
                                    <td>lymph node aspirates</td>
                                    <td>diagnosis</td>
                                    <td>adenocarcinoma, squamous cell carcinoma</td>
                                    <td>II, III, IV</td>
                                    <td>50</td>
                                    <td>31, 19</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>non-malignant</td>
                                    <td>29</td>
                                    <td>15, 14</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>LC</td>
                                    <td>ESI</td>
                                    <td>positive</td>
                                    <td>Q-TOF</td>
                                    <td>MS/MS</td>
                                    <td>MassHunter, MassProfilerProfessional</td>
                                    <td>HMDB</td>
                                    <td>OPLS-DA, PLS-DA</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>2018</td>
                                    <td>83</td>
                                </tr>

                                <tr>
                                    <td>US</td>
                                    <td>30104001</td>
                                    <td>Sappington et al. 2018</td>
                                    <td>#2</td>
                                    <td>adenocarcinoma vs. squamous cell carcinoma</td>
                                    <td>lymph node aspirates</td>
                                    <td>diagnosis</td>
                                    <td>adenocarcinoma</td>
                                    <td>II, III, IV</td>
                                    <td>31</td>
                                    <td>17, 14</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>squamous cell carcinoma</td>
                                    <td>19</td>
                                    <td>14, 5</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>LC</td>
                                    <td>ESI</td>
                                    <td>positive</td>
                                    <td>Q-TOF</td>
                                    <td>MS/MS</td>
                                    <td>MassHunter, MassProfilerProfessional</td>
                                    <td>HMDB</td>
                                    <td>OPLS-DA, PLS-DA</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>2018</td>
                                    <td>84</td>
                                </tr>

                                <tr>
                                    <td>China</td>
                                    <td>30805978</td>
                                    <td>Sun et al. 2019</td>
                                    <td>#1</td>
                                    <td>lung cancer vs. healthy</td>
                                    <td>serum</td>
                                    <td>diagnosis</td>
                                    <td>lung cancer</td>
                                    <td>I, II, III, IV</td>
                                    <td>31</td>
                                    <td>21, 10</td>
                                    <td>54.1 ±  9.9 </td>
                                    <td>smoker, non-smoker</td>
                                    <td>healthy</td>
                                    <td>29</td>
                                    <td>15, 14</td>
                                    <td>52.1 ± 14.6</td>
                                    <td>smoker, non-smoker</td>
                                    <td>GC</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>BinBase, KEGG</td>
                                    <td>Student t test, PLS-DA</td>
                                    <td>ROC curve analysis </td>
                                    <td>–</td>
                                    <td>2019</td>
                                    <td>85</td>
                                </tr>

                                <tr>
                                    <td>China</td>
                                    <td>25482491</td>
                                    <td>Wang et al. 2014</td>
                                    <td>#1</td>
                                    <td>adenocarcinoma + squamous cell carcinoma + adenosquamous carcinoma (preoperative contralateral) vs. adenocarcinoma + squamous cell carcinoma + adenosquamous carcinoma (preoperative ipsilateral)</td>
                                    <td>exhaled breath</td>
                                    <td>diagnosis</td>
                                    <td>adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma</td>
                                    <td>I, II, IV</td>
                                    <td>18</td>
                                    <td>13, 5</td>
                                    <td>58.67 ± 6.34</td>
                                    <td>smoker</td>
                                    <td>preoperative contralateral vs. preoperative ipsilateral</td>
                                    <td>18</td>
                                    <td>13, 5</td>
                                    <td>58.67 ± 6.34</td>
                                    <td>smoker</td>
                                    <td>GC</td>
                                    <td>EI</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>XCMS</td>
                                    <td>–</td>
                                    <td>PCA, PLS-DA, OPLS-DA, Kruskal-Wallis rank sum test</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>2014</td>
                                    <td>86</td>
                                </tr>

                                <tr>
                                    <td>China</td>
                                    <td>25482491</td>
                                    <td>Wang et al. 2014</td>
                                    <td>#2</td>
                                    <td>adenocarcinoma + squamous cell carcinoma + adenosquamous carcinoma (postoperative contralateral) vs. adenocarcinoma + squamous cell carcinoma + adenosquamous carcinoma (postoperative ipsilateral)</td>
                                    <td>exhaled breath</td>
                                    <td>diagnosis</td>
                                    <td>adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma</td>
                                    <td>I, II, IV</td>
                                    <td>18</td>
                                    <td>13, 5</td>
                                    <td>58.67 ± 6.34</td>
                                    <td>smoker</td>
                                    <td>postoperative contralateral vs. postoperative ipsilateral</td>
                                    <td>18</td>
                                    <td>13, 5</td>
                                    <td>58.67 ± 6.34</td>
                                    <td>smoker</td>
                                    <td>GC</td>
                                    <td>EI</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>XCMS</td>
                                    <td>–</td>
                                    <td>PCA, PLS-DA, OPLS-DA, Kruskal-Wallis rank sum test</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>2014</td>
                                    <td>87</td>
                                </tr>

                                <tr>
                                    <td>China</td>
                                    <td>25482491</td>
                                    <td>Wang et al. 2014</td>
                                    <td>#3</td>
                                    <td>adenocarcinoma + squamous cell carcinoma + adenosquamous carcinoma (ipsilateral lung preoperative) vs. adenocarcinoma + squamous cell carcinoma + adenosquamous carcinoma (postoperative)</td>
                                    <td>exhaled breath</td>
                                    <td>diagnosis</td>
                                    <td>adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma</td>
                                    <td>I, II, IV</td>
                                    <td>18</td>
                                    <td>13, 5</td>
                                    <td>58.67 ± 6.34</td>
                                    <td>smoker</td>
                                    <td>before vs. after treatment (operation)</td>
                                    <td>18</td>
                                    <td>13, 5</td>
                                    <td>58.67 ± 6.34</td>
                                    <td>smoker</td>
                                    <td>GC</td>
                                    <td>EI</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>XCMS</td>
                                    <td>–</td>
                                    <td>PCA, PLS-DA, OPLS-DA, Kruskal-Wallis rank sum test</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>2014</td>
                                    <td>88</td>
                                </tr>

                                <tr>
                                    <td>China</td>
                                    <td>25482491</td>
                                    <td>Wang et al. 2014</td>
                                    <td>#4</td>
                                    <td>adenocarcinoma + squamous cell carcinoma + adenosquamous carcinoma (preoperative) vs. adenocarcinoma + squamous cell carcinoma + adenosquamous carcinoma (postoperative)</td>
                                    <td>blood</td>
                                    <td>diagnosis</td>
                                    <td>adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma</td>
                                    <td>I, II, IV</td>
                                    <td>18</td>
                                    <td>13, 5</td>
                                    <td>58.67 ± 6.34</td>
                                    <td>smoker</td>
                                    <td>before vs. after treatment (operation)</td>
                                    <td>18</td>
                                    <td>13, 5</td>
                                    <td>58.67 ± 6.34</td>
                                    <td>smoker</td>
                                    <td>GC</td>
                                    <td>EI</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>XCMS</td>
                                    <td>–</td>
                                    <td>PCA, PLS-DA, OPLS-DA, Kruskal-Wallis rank sum test</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>2014</td>
                                    <td>89</td>
                                </tr>

                                <tr>
                                    <td>China</td>
                                    <td>23857124</td>
                                    <td>Wen et al. 2013</td>
                                    <td>#1</td>
                                    <td>adenocarcinoma vs. healthy</td>
                                    <td>plasma</td>
                                    <td>diagnosis</td>
                                    <td>adenocarcinoma</td>
                                    <td>I</td>
                                    <td>31</td>
                                    <td>15, 16</td>
                                    <td>median: 63 (40-81)</td>
                                    <td>smoker, non-smoker</td>
                                    <td>healthy</td>
                                    <td>28</td>
                                    <td>20, 8</td>
                                    <td>median: 37 (29-50)</td>
                                    <td>smoker, non-smoker</td>
                                    <td>GC</td>
                                    <td>EI</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>MassHunter, Mass Profiler Professional software (Agilent) </td>
                                    <td>NIST 08, HMDB, METLIN, LIPID MAPS</td>
                                    <td>Mann–Whitney–Wilcoxon test, OPLS-DA</td>
                                    <td>ROC curve analysis</td>
                                    <td>–</td>
                                    <td>2013</td>
                                    <td>90</td>
                                </tr>

                                <tr>
                                    <td>China</td>
                                    <td>23857124</td>
                                    <td>Wen et al. 2013</td>
                                    <td>#2</td>
                                    <td>adenocarcinoma vs. healthy</td>
                                    <td>plasma</td>
                                    <td>diagnosis</td>
                                    <td>adenocarcinoma</td>
                                    <td>I</td>
                                    <td>31</td>
                                    <td>15, 16</td>
                                    <td>median: 63 (40-81)</td>
                                    <td>smoker, non-smoker</td>
                                    <td>healthy</td>
                                    <td>28</td>
                                    <td>20, 8</td>
                                    <td>median: 37 (29-50)</td>
                                    <td>smoker, non-smoker</td>
                                    <td>LC</td>
                                    <td>ESI</td>
                                    <td>–</td>
                                    <td>Q-TOF</td>
                                    <td>MS/MS</td>
                                    <td>MassHunter, Mass Profiler Professional software (Agilent) </td>
                                    <td>NIST 08, HMDB, METLIN, LIPID MAPS</td>
                                    <td>Mann–Whitney–Wilcoxon test, OPLS-DA</td>
                                    <td>ROC curve analysis</td>
                                    <td>–</td>
                                    <td>2013</td>
                                    <td>91</td>
                                </tr>

                                <tr>
                                    <td>US</td>
                                    <td>26282655</td>
                                    <td>Wikoff et al. 2015a</td>
                                    <td>#1</td>
                                    <td>NSCLC vs. healthy</td>
                                    <td>serum</td>
                                    <td>prediagnosis</td>
                                    <td>NSCLC</td>
                                    <td>I, II, III, IV</td>
                                    <td>100</td>
                                    <td>75, 25</td>
                                    <td>61.1 ± 5.8</td>
                                    <td>former, current</td>
                                    <td>healthy </td>
                                    <td>199</td>
                                    <td>149, 50</td>
                                    <td>60.9 ± 5.9</td>
                                    <td>former, current</td>
                                    <td>LC</td>
                                    <td>ESI</td>
                                    <td>both</td>
                                    <td>Q-TOF</td>
                                    <td>MS/MS</td>
                                    <td>XCMS</td>
                                    <td>METLIN, LIPID MAPS, HMDB, Pubchem, SciFinder Scholar</td>
                                    <td>Mann-Whitney U test, Kruskal-Wallis test</td>
                                    <td>ROC curve</td>
                                    <td>–</td>
                                    <td>2015</td>
                                    <td>92</td>
                                </tr>

                                <tr>
                                    <td>US</td>
                                    <td>26282655</td>
                                    <td>Wikoff et al. 2015a</td>
                                    <td>#2</td>
                                    <td>NSCLC vs. healthy</td>
                                    <td>serum</td>
                                    <td>prediagnosis</td>
                                    <td>NSCLC</td>
                                    <td>I, II, III, IV</td>
                                    <td>108</td>
                                    <td>75, 33</td>
                                    <td>61.9 ± 5.7</td>
                                    <td>former, current</td>
                                    <td>healthy </td>
                                    <td>216</td>
                                    <td>150, 66</td>
                                    <td>61.9 ± 5.9</td>
                                    <td>former, current</td>
                                    <td>LC</td>
                                    <td>ESI</td>
                                    <td>both</td>
                                    <td>Q-TOF</td>
                                    <td>MS/MS</td>
                                    <td>XCMS</td>
                                    <td>METLIN, LIPID MAPS, HMDB, Pubchem, SciFinder Scholar</td>
                                    <td>Mann-Whitney U test, Kruskal-Wallis test</td>
                                    <td>ROC curve</td>
                                    <td>–</td>
                                    <td>2015</td>
                                    <td>93</td>
                                </tr>

                                <tr>
                                    <td>US</td>
                                    <td>25657018</td>
                                    <td>Wikoff et al. 2015b</td>
                                    <td>#1</td>
                                    <td>adenocarcinoma (tumor tissue) vs. adenocarcinoma (normal tissue)</td>
                                    <td>tissue</td>
                                    <td>diagnosis</td>
                                    <td>adenocarcinoma</td>
                                    <td>I</td>
                                    <td>39</td>
                                    <td>15, 24</td>
                                    <td>72.33 ± 8.78</td>
                                    <td>smoker, non-smoker</td>
                                    <td>tumor vs. adjacent normal tissue</td>
                                    <td>39</td>
                                    <td>15, 24</td>
                                    <td>72.33 ± 8.78</td>
                                    <td>smoker, non-smoker</td>
                                    <td>GC</td>
                                    <td>EI</td>
                                    <td>–</td>
                                    <td>TOF</td>
                                    <td>–</td>
                                    <td>BinBase</td>
                                    <td>NIST11, BinBase</td>
                                    <td>OPLS-DA</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>2015</td>
                                    <td>94</td>
                                </tr>

                                <tr>
                                    <td>China</td>
                                    <td>24771673</td>
                                    <td>Wu et al. 2014</td>
                                    <td>#1</td>
                                    <td>NSCLC vs. healthy</td>
                                    <td>urine</td>
                                    <td>diagnosis</td>
                                    <td>NSCLC </td>
                                    <td>–</td>
                                    <td>20</td>
                                    <td>10, 10</td>
                                    <td>38-74</td>
                                    <td>–</td>
                                    <td>healthy</td>
                                    <td>20</td>
                                    <td>10, 10</td>
                                    <td>35-66</td>
                                    <td>–</td>
                                    <td>LC</td>
                                    <td>ESI</td>
                                    <td>positive</td>
                                    <td>Q-TOF</td>
                                    <td>MS/MS</td>
                                    <td>MassLynx</td>
                                    <td>HMDB, METLIN, lipidmaps</td>
                                    <td>OPLS-DA, student’s t-test</td>
                                    <td>ROC curve analysis </td>
                                    <td>–</td>
                                    <td>2014</td>
                                    <td>95</td>
                                </tr>

                                <tr>
                                    <td>China</td>
                                    <td>24771673</td>
                                    <td>Wu et al. 2014</td>
                                    <td>#2</td>
                                    <td>NSCLC vs. healthy</td>
                                    <td>urine</td>
                                    <td>diagnosis</td>
                                    <td>NSCLC </td>
                                    <td>–</td>
                                    <td>20</td>
                                    <td>10, 10</td>
                                    <td>38-74</td>
                                    <td>–</td>
                                    <td>healthy</td>
                                    <td>20</td>
                                    <td>10, 10</td>
                                    <td>35-66</td>
                                    <td>–</td>
                                    <td>LC</td>
                                    <td>ESI</td>
                                    <td>negative</td>
                                    <td>Q-TOF</td>
                                    <td>MS/MS</td>
                                    <td>MassLynx</td>
                                    <td>HMDB, metlin, lipidmaps</td>
                                    <td>OPLS-DA, student’s t-test</td>
                                    <td>ROC curve analysis </td>
                                    <td>–</td>
                                    <td>2014</td>
                                    <td>96</td>
                                </tr>

                                <tr>
                                    <td>China</td>
                                    <td>29896992</td>
                                    <td>Xiang et al. 2018</td>
                                    <td>#1</td>
                                    <td>adenocarcinoma vs. healthy</td>
                                    <td>plasma</td>
                                    <td>diagnosis</td>
                                    <td>adenocarcinoma</td>
                                    <td>I, II, III, IV</td>
                                    <td>28</td>
                                    <td>16, 12</td>
                                    <td>59 (44-80)</td>
                                    <td>former, current, non-smoker</td>
                                    <td>healthy</td>
                                    <td>56</td>
                                    <td>35, 21</td>
                                    <td>58 (47-80)</td>
                                    <td>former, current, non-smoker</td>
                                    <td>LC</td>
                                    <td>ESI</td>
                                    <td>both</td>
                                    <td>LTQ-FT</td>
                                    <td>–</td>
                                    <td>Analyst software</td>
                                    <td>–</td>
                                    <td>independent sample t-tests, OPLS-DA</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>2018</td>
                                    <td>97</td>
                                </tr>

                                <tr>
                                    <td>China</td>
                                    <td>29896992</td>
                                    <td>Xiang et al. 2018</td>
                                    <td>#2</td>
                                    <td>adenocarcinoma vs. healthy</td>
                                    <td>plasma</td>
                                    <td>diagnosis</td>
                                    <td>adenocarcinoma</td>
                                    <td>I, II, III, IV</td>
                                    <td>24</td>
                                    <td>10, 14</td>
                                    <td>59 (43-71)</td>
                                    <td>former, current, non-smoker</td>
                                    <td>healthy</td>
                                    <td>56</td>
                                    <td>35, 21</td>
                                    <td>59 (42-79)</td>
                                    <td>former, current, non-smoker</td>
                                    <td>LC</td>
                                    <td>ESI</td>
                                    <td>both</td>
                                    <td>LTQ-FT</td>
                                    <td>–</td>
                                    <td>Analyst software</td>
                                    <td>–</td>
                                    <td>independent sample t-tests, OPLS-DA</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>2018</td>
                                    <td>98</td>
                                </tr>

                                <tr>
                                    <td>China</td>
                                    <td>29896992</td>
                                    <td>Xiang et al. 2018</td>
                                    <td>#3</td>
                                    <td>squamous cell carcinoma vs. healthy</td>
                                    <td>plasma</td>
                                    <td>diagnosis</td>
                                    <td>squamous cell carcinoma</td>
                                    <td>I, II, III, IV</td>
                                    <td>25</td>
                                    <td>21, 4</td>
                                    <td>59.8 (43-83)</td>
                                    <td>former, current, non-smoker</td>
                                    <td>healthy</td>
                                    <td>56</td>
                                    <td>35, 21</td>
                                    <td>58 (47-80)</td>
                                    <td>former, current, non-smoker</td>
                                    <td>LC</td>
                                    <td>ESI</td>
                                    <td>both</td>
                                    <td>LTQ-FT</td>
                                    <td>–</td>
                                    <td>Analyst software</td>
                                    <td>–</td>
                                    <td>independent sample t-tests, OPLS-DA</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>2018</td>
                                    <td>99</td>
                                </tr>

                                <tr>
                                    <td>China</td>
                                    <td>29896992</td>
                                    <td>Xiang et al. 2018</td>
                                    <td>#4</td>
                                    <td>squamous cell carcinoma vs. healthy</td>
                                    <td>plasma</td>
                                    <td>diagnosis</td>
                                    <td>squamous cell carcinoma</td>
                                    <td>I, II, III, IV</td>
                                    <td>22</td>
                                    <td>16, 6</td>
                                    <td>60.5 (42-73)</td>
                                    <td>former, current, non-smoker</td>
                                    <td>healthy</td>
                                    <td>56</td>
                                    <td>35, 21</td>
                                    <td>59 (42-79)</td>
                                    <td>former, current, non-smoker</td>
                                    <td>LC</td>
                                    <td>ESI</td>
                                    <td>both</td>
                                    <td>LTQ-FT</td>
                                    <td>–</td>
                                    <td>Analyst software</td>
                                    <td>–</td>
                                    <td>independent sample t-tests, OPLS-DA</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>2018</td>
                                    <td>100</td>
                                </tr>

                                <tr>
                                    <td>China</td>
                                    <td>20309903</td>
                                    <td>Yang et al. 2010</td>
                                    <td>#1</td>
                                    <td>adenocarcinoma + squamous cell cancer vs. healthy</td>
                                    <td>urine</td>
                                    <td>diagnosis</td>
                                    <td>adenocarcinoma, squamous cell carcinoma</td>
                                    <td>–</td>
                                    <td>35</td>
                                    <td>23, 12</td>
                                    <td>61.8 ± 13.3, 57.4 ± 9.8 </td>
                                    <td>–</td>
                                    <td>healthy</td>
                                    <td>32</td>
                                    <td>27, 5</td>
                                    <td>57.1 ± 9.9, 45.6 ± 10.8 </td>
                                    <td>–</td>
                                    <td>LC</td>
                                    <td>ESI</td>
                                    <td>positive </td>
                                    <td>QTRAP </td>
                                    <td>MS/MS</td>
                                    <td>MarkerView </td>
                                    <td>HMDB, KEGG, Pubchem, mass bank </td>
                                    <td>OSC PLS-DA</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>2010</td>
                                    <td>101</td>
                                </tr>

                                <tr>
                                    <td>China</td>
                                    <td>31884394</td>
                                    <td>Yang et al. 2020</td>
                                    <td>#1</td>
                                    <td>adenocarcinoma vs. pulmonary tuberculosis + other pulmonary diseases</td>
                                    <td>pleural effusion</td>
                                    <td>diagnosis</td>
                                    <td>adenocarcinoma</td>
                                    <td>–</td>
                                    <td>46</td>
                                    <td>15, 31</td>
                                    <td>63 ± 12</td>
                                    <td>–</td>
                                    <td>pulmonary tuberculosis, other pulmonary diseases</td>
                                    <td>32</td>
                                    <td>26, 6</td>
                                    <td>49 ± 19</td>
                                    <td>–</td>
                                    <td>LC</td>
                                    <td>ESI</td>
                                    <td>both</td>
                                    <td>Q-Orbitrap</td>
                                    <td>MS/MS</td>
                                    <td>XCMS</td>
                                    <td>HMDB, METLIN, LipidSearch </td>
                                    <td>PLS-DA</td>
                                    <td>ROC analysis</td>
                                    <td>–</td>
                                    <td>2020</td>
                                    <td>102</td>
                                </tr>

                                <tr>
                                    <td>China</td>
                                    <td>30473010</td>
                                    <td>Yue et al. 2018</td>
                                    <td>#1</td>
                                    <td>SCLC vs. healthy</td>
                                    <td>plasma</td>
                                    <td>diagnosis</td>
                                    <td>SCLC</td>
                                    <td>–</td>
                                    <td>20</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>healthy</td>
                                    <td>20</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>LC</td>
                                    <td>ESI</td>
                                    <td>both</td>
                                    <td>QTRAP</td>
                                    <td>MS/MS</td>
                                    <td>Analyst, MultiQuant</td>
                                    <td>–</td>
                                    <td>OPLS-DA, student’s t-test</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>2018</td>
                                    <td>103</td>
                                </tr>

                                <tr>
                                    <td>Canada</td>
                                    <td>34208545</td>
                                    <td>Ahmed et al. 2021</td>
                                    <td>#1</td>
                                    <td>NSCLC pre-surgery vs. NSCLC post-surgery</td>
                                    <td>Urine</td>
                                    <td>diagnosis</td>
                                    <td>NSCLC pre-surgery </td>
                                    <td>I, II</td>
                                    <td>29</td>
                                    <td>11, 18</td>
                                    <td>63.8 ± 7.0</td>
                                    <td>former, current, non-smoker</td>
                                    <td>NSCLC post-surgery</td>
                                    <td>29</td>
                                    <td>11,18</td>
                                    <td>63.8 ± 7.0</td>
                                    <td>former, current, non-smoker</td>
                                    <td>LC</td>
                                    <td>ESI</td>
                                    <td>both</td>
                                    <td>Q-TOF</td>
                                    <td>–</td>
                                    <td>MassHunter, Mass Profiler Professional</td>
                                    <td>HMDB, METLIN</td>
                                    <td>Pair t-test, </td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>2021</td>
                                    <td>104</td>
                                </tr>

                                <tr>
                                    <td>Canada</td>
                                    <td>34208545</td>
                                    <td>Ahmed et al. 2021</td>
                                    <td>#2</td>
                                    <td>NSCLC pre-surgery vs. NSCLC post-surgery</td>
                                    <td>Serum</td>
                                    <td>diagnosis</td>
                                    <td>NSCLC pre-surgery </td>
                                    <td>I, II</td>
                                    <td>32</td>
                                    <td>12, 20</td>
                                    <td>63.8 ± 7.0</td>
                                    <td>former, current, non-smoker</td>
                                    <td>NSCLC post-surgery</td>
                                    <td>32</td>
                                    <td>12,20</td>
                                    <td>63.8 ± 7.0</td>
                                    <td>former, current, non-smoker</td>
                                    <td>LC</td>
                                    <td>ESI</td>
                                    <td>both</td>
                                    <td>Q-TOF</td>
                                    <td>–</td>
                                    <td>MassHunter, Mass Profiler Professional</td>
                                    <td>HMDB, METLIN</td>
                                    <td>Pair t-test, </td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>2021</td>
                                    <td>105</td>
                                </tr>

                                <tr>
                                    <td>China</td>
                                    <td>34083687</td>
                                    <td>Qi et al. 2021</td>
                                    <td>#1</td>
                                    <td>adenocarcinoma + squamous cell carcinoma +  small cell lung cancer + other types + unknown types vs. healthy control</td>
                                    <td>blood</td>
                                    <td>diagnosis</td>
                                    <td>adenocarcinoma, squamous cell carcinoma, small cell lung cancer, other types, unknown types</td>
                                    <td>I, II, III, IV</td>
                                    <td>98</td>
                                    <td>51, 47</td>
                                    <td>Median: 50 (32-69)</td>
                                    <td>–</td>
                                    <td>healthy</td>
                                    <td>75</td>
                                    <td>36, 39</td>
                                    <td>Median: 50 (31-69)</td>
                                    <td>–</td>
                                    <td>LC</td>
                                    <td>ESI</td>
                                    <td>both</td>
                                    <td>Q-Orbitrap</td>
                                    <td>MS/MS</td>
                                    <td>ProteoWizard, XCMS, Xcalibur, CAMERA, Compound Discoverer</td>
                                    <td>x</td>
                                    <td>PCA, OPLS-DA, Student’s t test </td>
                                    <td>ROC analysis</td>
                                    <td>–</td>
                                    <td>2021</td>
                                    <td>106</td>
                                </tr>

                                <tr>
                                    <td>China</td>
                                    <td>34136379</td>
                                    <td>Wan et al. 2021</td>
                                    <td>#1</td>
                                    <td>squamous cell carcinomas + adenocarcinomas vs. healthy control</td>
                                    <td>Serum</td>
                                    <td>diagnosis</td>
                                    <td>squamous cell carcinoma, adenocarcinomas</td>
                                    <td>I, II</td>
                                    <td>48</td>
                                    <td>21, 27</td>
                                    <td>59.1 (38-75)</td>
                                    <td>smoker, non-smoker</td>
                                    <td>healthy</td>
                                    <td>30</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>LC</td>
                                    <td>ESI</td>
                                    <td>both</td>
                                    <td>Q-TOF</td>
                                    <td>–</td>
                                    <td>Progenesis QI 2.3 </td>
                                    <td>HMDB, Metlin</td>
                                    <td>PCA, OPLS-DA, Student’s t test </td>
                                    <td>ROC analysis</td>
                                    <td>–</td>
                                    <td>2021</td>
                                    <td>107</td>
                                </tr>

                                <tr>
                                    <td>China</td>
                                    <td>34056907</td>
                                    <td>Zheng et al. 2021 </td>
                                    <td>#1</td>
                                    <td>lung cancer vs. healthy control</td>
                                    <td>Serum</td>
                                    <td>diagnosis</td>
                                    <td>lung cancer</td>
                                    <td>I, II, III, IV</td>
                                    <td>57</td>
                                    <td>38, 19</td>
                                    <td>Median: 62 (52-69)</td>
                                    <td>smoker, non-smoker</td>
                                    <td>healthy</td>
                                    <td>59</td>
                                    <td>48, 11</td>
                                    <td>Median: 60 (59-62)</td>
                                    <td>smoker, non-smoker</td>
                                    <td>GC</td>
                                    <td>EI</td>
                                    <td>–</td>
                                    <td>quadrupole</td>
                                    <td>–</td>
                                    <td>MassHunter Workstation software, Mass Profiler Professional software </td>
                                    <td>NIST14, HMDB, Golm Metabolome Database</td>
                                    <td>Student’s t-test, Mann–Whitney U test, PCA, PLS-DA, and OPLS-DA</td>
                                    <td>ROC analysis</td>
                                    <td>–</td>
                                    <td>2021</td>
                                    <td>108</td>
                                </tr>

                                <tr>
                                    <td>China</td>
                                    <td>32693607</td>
                                    <td>You et al. 2020 </td>
                                    <td>#1</td>
                                    <td>AC vs. SCC</td>
                                    <td>tissue</td>
                                    <td>diagnosis</td>
                                    <td>AC</td>
                                    <td>I, II, III</td>
                                    <td>45</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>SCC</td>
                                    <td>18</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>LC</td>
                                    <td>ESI</td>
                                    <td>both</td>
                                    <td>Q-TOF</td>
                                    <td>MS/MS</td>
                                    <td>MarkerView workstation, MultiQuant 3.0.3</td>
                                    <td>OSI-SMMS</td>
                                    <td>PCA, PLS-DA, non-parametric test </td>
                                    <td>ROC analysis</td>
                                    <td>–</td>
                                    <td>2020</td>
                                    <td>109</td>
                                </tr>

                                <tr>
                                    <td>China</td>
                                    <td>32693607</td>
                                    <td>You et al. 2020 </td>
                                    <td>#2</td>
                                    <td>lung carcinoma tissue vs. benign lung tissue</td>
                                    <td>tissue</td>
                                    <td>diagnosis</td>
                                    <td>NSCLC</td>
                                    <td>I, II, III</td>
                                    <td>85</td>
                                    <td>51, 34</td>
                                    <td>59 ± 12</td>
                                    <td>–</td>
                                    <td>benign lung tissues </td>
                                    <td>85</td>
                                    <td>51, 34</td>
                                    <td>59 ± 12</td>
                                    <td>–</td>
                                    <td>LC</td>
                                    <td>ESI</td>
                                    <td>both</td>
                                    <td>Q-TOF</td>
                                    <td>MS/MS</td>
                                    <td>MarkerView workstation, MultiQuant 3.0.3</td>
                                    <td>OSI-SMMS</td>
                                    <td>PCA, PLS-DA, non-parametric test </td>
                                    <td>ROC analysis</td>
                                    <td>–</td>
                                    <td>2020</td>
                                    <td>110</td>
                                </tr>

                                <tr>
                                    <td>China</td>
                                    <td>32145537</td>
                                    <td>Noreldeen et al. 2020 </td>
                                    <td>#1</td>
                                    <td>non-small cell lung cancer vs. healthy control</td>
                                    <td>Serum</td>
                                    <td>diagnosis</td>
                                    <td>non-small cell lung cancer</td>
                                    <td>I, II, III, IV</td>
                                    <td>39</td>
                                    <td>0, 39</td>
                                    <td>61.64 ± 11.60</td>
                                    <td>–</td>
                                    <td>healthy control </td>
                                    <td>46</td>
                                    <td>0, 46</td>
                                    <td>55.26 ± 16.24</td>
                                    <td>–</td>
                                    <td>LC</td>
                                    <td>ESI</td>
                                    <td>both</td>
                                    <td>Q-TOF</td>
                                    <td>MS/MS</td>
                                    <td>Peakview workstation, Multiquant software</td>
                                    <td>in-house database</td>
                                    <td>PLS-DA, Mann-Whitney test </td>
                                    <td>ROC analysis</td>
                                    <td>–</td>
                                    <td>2020</td>
                                    <td>111</td>
                                </tr>

                                <tr>
                                    <td>China</td>
                                    <td>34527604</td>
                                    <td>Zhao et al. 2021 </td>
                                    <td>#1</td>
                                    <td>LCC + ADC + SCC + SCLC vs. healthy control </td>
                                    <td>Serum</td>
                                    <td>diagnosis</td>
                                    <td>LCC, ADC, SCC, SCLC</td>
                                    <td>I, II, III, IV</td>
                                    <td>39</td>
                                    <td>21, 23</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>healthy control </td>
                                    <td>40</td>
                                    <td>18, 27</td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>LC</td>
                                    <td>ESI</td>
                                    <td>both</td>
                                    <td>Q-TOF</td>
                                    <td>MS/MS</td>
                                    <td>XCMS, CAMERA, metaX</td>
                                    <td>KEGG, HMDB</td>
                                    <td>Student’s t-test, PLS-DA, </td>
                                    <td>ROC analysis</td>
                                    <td>–</td>
                                    <td>2021</td>
                                    <td>112</td>
                                </tr>

                                <tr>
                                    <td>Poland</td>
                                    <td>34282765</td>
                                    <td>Kowalczyk et al. 2021 </td>
                                    <td>#1</td>
                                    <td>adenocarcinoma (ADC) vs. healthy control </td>
                                    <td>Tissue</td>
                                    <td>diagnosis</td>
                                    <td>adenocarcinoma (ADC)</td>
                                    <td>I, II, III</td>
                                    <td>33</td>
                                    <td>23, 10</td>
                                    <td>64.77 ± 8.44</td>
                                    <td>–</td>
                                    <td>healthy control </td>
                                    <td>20</td>
                                    <td>13, 7</td>
                                    <td>61.5 ± 12.06</td>
                                    <td>–</td>
                                    <td>LC</td>
                                    <td>ESI</td>
                                    <td>both</td>
                                    <td>Q-TOF</td>
                                    <td>–</td>
                                    <td>Mass Hunter Qualitative Analysis Software, Mass Profiler Professional </td>
                                    <td>METLIN, KEGG, LIPIDMAPS, and HMDB</td>
                                    <td>Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) </td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>2021</td>
                                    <td>113</td>
                                </tr>

                                <tr>
                                    <td>Poland</td>
                                    <td>34282765</td>
                                    <td>Kowalczyk et al. 2021 </td>
                                    <td>#2</td>
                                    <td>squemous cell carcinoma (SCC) vs. healthy control </td>
                                    <td>Tissue</td>
                                    <td>diagnosis</td>
                                    <td>squemous cell carcinoma (SCC)</td>
                                    <td>I, II, III</td>
                                    <td>54</td>
                                    <td>39, 15</td>
                                    <td>64.45 ± 8.02</td>
                                    <td>–</td>
                                    <td>healthy control </td>
                                    <td>20</td>
                                    <td>13, 7</td>
                                    <td>61.5 ± 12.06</td>
                                    <td>–</td>
                                    <td>LC</td>
                                    <td>ESI</td>
                                    <td>both</td>
                                    <td>Q-TOF</td>
                                    <td>–</td>
                                    <td>Mass Hunter Qualitative Analysis Software, Mass Profiler Professional </td>
                                    <td>METLIN, KEGG, LIPIDMAPS, and HMDB</td>
                                    <td>Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) </td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>2021</td>
                                    <td>114</td>
                                </tr>

                                <tr>
                                    <td>Poland</td>
                                    <td>34282765</td>
                                    <td>Kowalczyk et al. 2021 </td>
                                    <td>#3</td>
                                    <td>squemous cell carcinoma (SCC) vs. adenocarcinoma (ADC)</td>
                                    <td>Tissue</td>
                                    <td>diagnosis</td>
                                    <td>squemous cell carcinoma (SCC)</td>
                                    <td>I, II, III</td>
                                    <td>54</td>
                                    <td>39, 15</td>
                                    <td>64.45 ± 8.02</td>
                                    <td>–</td>
                                    <td>adenocarcinoma (ADC)</td>
                                    <td>33</td>
                                    <td>23, 10</td>
                                    <td>64.77 ± 8.44</td>
                                    <td>–</td>
                                    <td>LC</td>
                                    <td>ESI</td>
                                    <td>both</td>
                                    <td>Q-TOF</td>
                                    <td>–</td>
                                    <td>Mass Hunter Qualitative Analysis Software, Mass Profiler Professional </td>
                                    <td>METLIN, KEGG, LIPIDMAPS, and HMDB</td>
                                    <td>Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) </td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>2021</td>
                                    <td>115</td>
                                </tr>

                                <tr>
                                    <td>Poland</td>
                                    <td>34282765</td>
                                    <td>Kowalczyk et al. 2021 </td>
                                    <td>#4</td>
                                    <td>adenocarcinoma (ADC) vs. healthy control </td>
                                    <td>Plasma</td>
                                    <td>diagnosis</td>
                                    <td>adenocarcinoma (ADC)</td>
                                    <td>I, II, III</td>
                                    <td>32</td>
                                    <td>20, 12</td>
                                    <td>64.16 ± 6.91</td>
                                    <td>–</td>
                                    <td>healthy control </td>
                                    <td>20</td>
                                    <td>13, 7</td>
                                    <td>61.5 ± 12.06</td>
                                    <td>–</td>
                                    <td>LC</td>
                                    <td>ESI</td>
                                    <td>both</td>
                                    <td>Q-TOF</td>
                                    <td>–</td>
                                    <td>Mass Hunter Qualitative Analysis Software, Mass Profiler Professional </td>
                                    <td>METLIN, KEGG, LIPIDMAPS, and HMDB</td>
                                    <td>Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) </td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>2021</td>
                                    <td>116</td>
                                </tr>

                                <tr>
                                    <td>Poland</td>
                                    <td>34282765</td>
                                    <td>Kowalczyk et al. 2021 </td>
                                    <td>#5</td>
                                    <td>squemous cell carcinoma (SCC) vs. healthy control </td>
                                    <td>Plasma</td>
                                    <td>diagnosis</td>
                                    <td>squemous cell carcinoma (SCC)</td>
                                    <td>I, II, III</td>
                                    <td>33</td>
                                    <td>21, 12</td>
                                    <td>64.45 ± 8.77</td>
                                    <td>–</td>
                                    <td>healthy control </td>
                                    <td>20</td>
                                    <td>13, 7</td>
                                    <td>61.5 ± 12.06</td>
                                    <td>–</td>
                                    <td>LC</td>
                                    <td>ESI</td>
                                    <td>both</td>
                                    <td>Q-TOF</td>
                                    <td>–</td>
                                    <td>Mass Hunter Qualitative Analysis Software, Mass Profiler Professional </td>
                                    <td>METLIN, KEGG, LIPIDMAPS, and HMDB</td>
                                    <td>Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) </td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>2021</td>
                                    <td>117</td>
                                </tr>

                                <tr>
                                    <td>Poland</td>
                                    <td>34282765</td>
                                    <td>Kowalczyk et al. 2021 </td>
                                    <td>#6</td>
                                    <td>squemous cell carcinoma (SCC) vs. adenocarcinoma (ADC)</td>
                                    <td>Plasma</td>
                                    <td>diagnosis</td>
                                    <td>squemous cell carcinoma (SCC)</td>
                                    <td>I, II, III</td>
                                    <td>33</td>
                                    <td>21, 12</td>
                                    <td>64.45 ± 8.77</td>
                                    <td>–</td>
                                    <td>adenocarcinoma (ADC)</td>
                                    <td>32</td>
                                    <td>20, 12</td>
                                    <td>64.16 ± 6.91</td>
                                    <td>–</td>
                                    <td>LC</td>
                                    <td>ESI</td>
                                    <td>both</td>
                                    <td>Q-TOF</td>
                                    <td>–</td>
                                    <td>Mass Hunter Qualitative Analysis Software, Mass Profiler Professional </td>
                                    <td>METLIN, KEGG, LIPIDMAPS, and HMDB</td>
                                    <td>Mann–Whitney U-test and Benjamini–Hochberg false discovery rate, partial least squares discriminant analysis (PLS-DA) </td>
                                    <td>–</td>
                                    <td>–</td>
                                    <td>2021</td>
                                    <td>118</td>
                                </tr>

                                <tr>
                                    <td>Taiwan</td>
                                    <td>34193905</td>
                                    <td>Chen et al. 2021 </td>
                                    <td>#1</td>
                                    <td>squamous cell carcinoma + adenocarcinoma + small cell lung cancer vs. non-malignant control </td>
                                    <td>Pleural effusion</td>
                                    <td>diagnosis</td>
                                    <td>squamous cell carcinoma, adenocarcinoma, small cell lung cancer</td>
                                    <td>–</td>
                                    <td>38</td>
                                    <td>24, 14</td>
                                    <td>65.7 ± 12.4</td>
                                    <td>current, former, never smoker, enviromental tobacco </td>
                                    <td>non-malignant control </td>
                                    <td>30</td>
                                    <td>17, 13</td>
                                    <td>77.5 ± 13.1</td>
                                    <td>current, former, never smoker, enviromental tobacco </td>
                                    <td>GC</td>
                                    <td>EI</td>
                                    <td>–</td>
                                    <td>quadrupole</td>
                                    <td>–</td>
                                    <td>Mzmine</td>
                                    <td>KEGG</td>
                                    <td>Student’s t-test, PCA, PLS-DA</td>
                                    <td>ROC analysis</td>
                                    <td>–</td>
                                    <td>2021</td>
                                    <td>119</td>
                                </tr>

                                <tr>
                                    <td>China</td>
                                    <td>34342461</td>
                                    <td>Jiang et al. 2021 </td>
                                    <td>#1</td>
                                    <td>lung cancer vs. healthy control</td>
                                    <td>Saliva</td>
                                    <td>diagnosis</td>
                                    <td>lung cancer</td>
                                    <td>I </td>
                                    <td>45</td>
                                    <td>16, 29</td>
                                    <td>Median: 57.8 </td>
                                    <td>smoker, non-smoker</td>
                                    <td>healthy</td>
                                    <td>25</td>
                                    <td>10, 15</td>
                                    <td>Median: 52.9</td>
                                    <td>smoker, non-smoker</td>
                                    <td>–</td>
                                    <td>MALDI</td>
                                    <td>negative</td>
                                    <td>TOF/TOF</td>
                                    <td>MS/MS</td>
                                    <td>FlexAnalysis, ClinproTools software, R script </td>
                                    <td>HMDB</td>
                                    <td>Student’s t-test, PCA, Cluster analysis by Matlab. OPLS-DA</td>
                                    <td>ROC analysis</td>
                                    <td>–</td>
                                    <td>2021</td>
                                    <td>120</td>
                                </tr>

                        </tbody>

                      </table>
                    </div>
                    </div>
                  </div>
                </div>
            </div>
        </div>


        <link rel="stylesheet" type="text/css" href="https://cdn.datatables.net/1.11.5/css/jquery.dataTables.min.css">
        <script charset="utf8" src="https://code.jquery.com/jquery-3.6.0.min.js"></script> <!-- jQuery -->
        <script charset="utf8" src="https://cdn.datatables.net/1.11.5/js/jquery.dataTables.min.js"></script>



        <script type="text/javascript" src="/static/browse/js/browse_studies.js"></script>


        </div>

        <div class="text-center mt-5">
            <p>копирайт © ЛФиМА bebris</p>
        </div>

        <!-- Bootstrap core JS-->
        <script src="https://cdn.jsdelivr.net/npm/bootstrap@5.1.3/dist/js/bootstrap.bundle.min.js"></script>
        <!-- Core theme JS-->
        <script src="js/scripts.js"></script>
    </body>
</html>
